IperionX Limited (IPX) 20-F 18 Sep 23 2023 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2023 shares
Entity Addresses [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Jun. 30, 2023
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41338
Entity Registrant Name	IPERIONX Ltd
Entity Central Index Key	0001898601
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	129 W Trade Street
Entity Address, Address Line Two	Suite 1405
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28202
Entity Address, Country	US
Title of 12(b) Security	American Depositary Shares each representing 10 Ordinary Shares, no par value
Trading Symbol	IPX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	193,493,973
Auditor Firm ID	1379
Auditor Name	PricewaterhouseCoopers
Auditor Location	Perth, Australia
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	129 W Trade Street
Entity Address, Address Line Two	Suite 1405
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Contact Personnel Name	Anastasios Arima
Contact Personnel Email Address	info@iperionx.com
Entity Address, Postal Zip Code	28202
City Area Code	704
Local Phone Number	578-3217

CONSOLIDATED STATEMENT OF PROFI

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - USD ($)		11 Months Ended	12 Months Ended
		Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Continuing operations
Exploration and evaluation expenses		$ (2,328,386)	$ (2,826,397)	$ (6,189,159)
Research and development costs		(240,000)	(5,600,653)	(1,079,109)
Corporate and administrative expenses		(852,944)	(3,990,672)	(3,056,249)
Business development expenses		(581,200)	(2,654,420)	(3,205,162)
Share-based payment expenses		(4,084,764)	(2,589,413)	(8,340,328)
Finance income		5,075	494,469	401,045
Finance costs		(7,492)	(88,138)	(52,275)
Other income and expenses		(5,141,126)	(189,530)	0
Loss before income tax		(13,230,837)	(17,444,754)	(21,521,237)
Income tax expense		0	0	0
Loss for the year		(13,230,837)	(17,444,754)	(21,521,237)
Loss attributable to shareholders of IperionX Limited		(13,230,837)	(17,444,754)	(21,521,237)
Items that may be reclassified subsequently to profit or loss:
Exchange differences arising on translation into presentation currency		(2,419)	(411,913)	(593,912)
Other comprehensive loss for the year, net of tax		(2,419)	(411,913)	(593,912)
Total comprehensive loss for the year		(13,233,256)	(17,856,667)	(22,115,149)
Total comprehensive loss attributable to shareholders of IperionX Limited		$ (13,233,256)	$ (17,856,667)	$ (22,115,149)
Basic loss per share (in dollars per share)	[1]	$ (0.19)	$ (0.11)	$ (0.16)
Diluted loss per share (in dollars per share)	[1]	$ (0.19)	$ (0.11)	$ (0.16)
[1]Basic and diluted loss per share for the comparative period from July 20, 2020 to June 30, 2021 have been revised. Refer to Note 1(a) for further information.

CONSOLIDATED STATEMENT OF FINAN

CONSOLIDATED STATEMENT OF FINANCIAL POSITION - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current Assets
Cash and cash equivalents	$ 11,937,941	$ 5,672,551
Trade and other receivables	228,395	22,540
Prepayments	588,395	144,183
Total Current Assets	12,754,731	5,839,274
Non-Current Assets
Exploration and evaluation assets	3,059,021	2,431,229
Property, plant and equipment	3,989,783	1,387,986
Prepayments	3,000,000	0
Other financial assets	0	250,000
Total Non-Current Assets	10,048,804	4,069,215
TOTAL ASSETS	22,803,535	9,908,489
Current Liabilities
Trade and other payables	1,180,984	1,899,348
Loans and borrowings	382,626	134,247
Provisions	84,009	46,392
Total Current Liabilities	1,647,619	2,079,987
Non-Current Liabilities
Loans and borrowings	592,688	408,783
Total Non-Current Liabilities	592,688	408,783
TOTAL LIABILITIES	2,240,307	2,488,770
NET ASSETS	20,563,228	7,419,719
EQUITY
Contributed equity	58,764,248	29,782,268
Reserves	13,995,808	12,389,525
Accumulated losses	(52,196,828)	(34,752,074)
TOTAL EQUITY	$ 20,563,228	$ 7,419,719

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - USD ($)	Total	Contributed Equity [Member]	Share-Based Payments Reserve [Member]	Foreign Currency Translation Reserve [Member]	Accumulated Losses [Member]
Beginning balance at Jul. 19, 2020	$ 0	$ 0	$ 0	$ 0	$ 0
Changes in equity
Net loss for the year	(13,230,837)	0	0	0	(13,230,837)
Exchange differences arising on translation into presentation currency	(2,419)	0	0	(2,419)	0
Total comprehensive loss for the year	(13,233,256)	0	0	(2,419)	(13,230,837)
Issue of shares - incorporation	1	1	0	0	0
Issue of shares - seed placement	54,011	54,011	0	0	0
Reverse acquisition	6,548,856	5,581,274	967,582	0	0
Issue of shares - to facilitators of reverse acquisition	852,478	852,478	0	0	0
Issue of shares - share placement	2,819,340	2,819,340	0	0	0
Issue of shares - exercise of options and performance rights	719,393	1,033,732	(314,339)	0	0
Share issue costs	(85,467)	(85,467)	0	0	0
Share-based payment expense	4,084,764	0	4,084,764	0	0
Ending balance at Jun. 30, 2021	1,760,120	10,255,369	4,738,007	(2,419)	(13,230,837)
Changes in equity
Net loss for the year	(21,521,237)	0	0	0	(21,521,237)
Exchange differences arising on translation into presentation currency	(593,912)	0	0	(593,912)	0
Total comprehensive loss for the year	(22,115,149)	0	0	(593,912)	(21,521,237)
Issue of shares - share placement	17,604,000	17,604,000	0	0	0
Issue of shares - exercise of options	2,261,225	2,353,704	(92,479)	0	0
Share issue costs	(430,805)	(430,805)	0	0	0
Share-based payment expense	8,340,328	0	8,340,328	0	0
Ending balance at Jun. 30, 2022	7,419,719	29,782,268	12,985,856	(596,331)	(34,752,074)
Changes in equity
Net loss for the year	(17,444,754)	0	0	0	(17,444,754)
Exchange differences arising on translation into presentation currency	(411,913)	0	0	(411,913)	0
Total comprehensive loss for the year	(17,856,667)	0	0	(411,913)	(17,444,754)
Issue of shares - share placement	29,637,300	29,637,300	0	0	0
Issue of shares - exercise of options	284,645	477,156	(192,511)	0	0
Issue of shares - conversion of RSUs	0	167,487	(167,487)	0	0
Issue of shares - conversion of rights	0	216,007	(216,007)	0	0
Issue of shares to consultant	0	350,000	(350,000)	0	0
Share issue costs	(1,511,182)	(1,865,970)	354,788	0	0
Share-based payment expense	2,589,413	0	2,589,413	0	0
Ending balance at Jun. 30, 2023	$ 20,563,228	$ 58,764,248	$ 15,004,052	$ (1,008,244)	$ (52,196,828)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Payments to suppliers and employees	$ (3,562,589)	$ (15,954,550)	$ (12,112,577)
Interest paid	(511)	(49,488)	(45,541)
Interest received	5,075	139,644	24,041
Net cash flows used in operating activities	(3,558,025)	(15,864,394)	(12,134,077)
Investing activities
Purchase of exploration and evaluation assets	(504,750)	(627,792)	(1,926,479)
Purchase of property, plant and equipment	(66,818)	(2,077,794)	(889,988)
Blacksand option prepayments	0	(3,000,000)	0
Purchase of financial assets	0	0	(250,000)
Net cash flows used in investing activities	(571,568)	(5,705,586)	(3,066,467)
Financing activities
Proceeds from issue of shares	3,592,745	29,921,945	19,865,225
Share issue costs	(85,467)	(1,511,182)	(430,805)
Proceeds from borrowings	0	0	38,682
Repayment of borrowings	0	(5,594)	(2,225)
Payment of principal portion of lease liabilities	(6,473)	(512,660)	(78,778)
Net cash inflow on reverse acquisition	2,329,111	0	0
Net cash flows from financing activities	5,829,916	27,892,509	19,392,099
Net increase in cash and cash equivalents	1,700,323	6,322,529	4,191,555
Net foreign exchange differences	(2,419)	(57,139)	(216,908)
Cash and cash equivalents at beginning of the year	0	5,672,551	1,697,904
Cash and cash equivalents at the end of the year	$ 1,697,904	$ 11,937,941	$ 5,672,551

STATEMENT OF SIGNIFICANT ACCOUN

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2023
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES	1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies adopted in preparing the consolidated financial statements of IperionX Limited (“IperionX” or “Company”) and its consolidated entities (“Consolidated Entity” or “Group”) for the years ended June 30, 2023 and 2022 and for the period from July 20, 2020 to June 30, 2021 are stated to assist in a general understanding of the consolidated financial statements. IperionX is a for-profit company limited by shares, incorporated and domiciled in Australia. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX”, and our American Depository Shares, or ADSs, each representing ten (10) of our ordinary shares, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”. The principal activities of the Group during the year ended June 30, 2023 consisted of the exploration and evaluation of its mineral properties in the United States and the research and development of its associated and metals technologies to support an integrated titanium processing operation. The consolidated financial statements of the Group for the year ended June 30, 2023 were authorised for issue in accordance with a resolution of the Directors on September 15, 2023. (a) Basis of preparation The financial report is a general purpose financial report, which has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial report has also been prepared on a historical cost basis, except for other financial assets, which have been measured at fair value. The consolidated financial statements are presented in United States dollars (US$). Going concern The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business. The Group currently has no source of material operating cash inflows and had net outflows from operating and investing activities of US$21,569,980 for fiscal 2023 (2022: US$15,200,544). At June 30, 2023, the Group has cash and cash equivalents of US$11,937,941 (2022: US$5,672,551). The ongoing operation of the Group is dependent upon raising further additional funding from shareholders or other parties. In light of increasing expenditures to be incurred in executing on the Group’s current strategic plans to commercialize the Group’s titanium metal technologies and develop economically recoverable mineral deposits from the Group’s exploration properties, the Group is dependent on obtaining financing through equity financing, debt financing or other means. In the longer term, if the Group’s exploration, appraisal, and pilot activities are ultimately successful, additional funds will be required to develop the Group’s titanium metal technologies and exploration properties and commence commercial production. The ability to arrange such funding in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Group. There is no assurance that the Group will be successful in its efforts to raise additional funding on terms satisfactory to the Group. If the Group does not obtain additional funding, it may not be able to continue its operations as a going concern and therefore may not be able to realize its assets and extinguish its liabilities in the ordinary course of operations and at the amounts stated in the financial statements. Alternatively, the Group may be required to delay, reduce the scope of, or eliminate its current or future exploration, appraisal, and pilot activities or relinquish rights to certain of its interests. The Directors are confident that they will be able to raise additional funds as required to meet its obligations as and when they fall due and are of the opinion that the use of the going concern basis remains appropriate. However as a result of these matters, there is a material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (“PCAOB”) standards) on the Group’s ability to continue as a going concern, and therefore the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. Comparative figures When applicable, certain comparative figures have been adjusted to conform to the current year’s presentation. These changes had no impact on the Group’s net loss or financial position for the year ended June 30, 2022 or period from July 20, 2020 to June 30, 2021. In the comparative figures for the period from July 20, 2020 to June 30, 2021, the Group has revised the loss per share in the consolidated statement of profit or loss to reflect the impact of the reverse acquisition in determining the weighted average number of ordinary shares. The revision reduces the basic and diluted loss per share from US$0.22 to US$0.19 per share. This change had no impact on the Group’s net loss or financial position for the period ended June 30, 2021. Whilst the Group considers the change to be immaterial, the Group has revised the previously reported loss per share presented for comparative purposes. (b) New standards, interpretations and amendments In the current year, the Group has adopted all of the new and revised Accounting Standards and Interpretations effective from July 1, 2022 that are mandatory. The adoption of the aforementioned standards has no impact on the financial statements of the Company as at June 30, 2023. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. (c) Issued standards and interpretations not early adopted International Financial Reporting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the year ended June 30, 2023. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group’s financial statements: Standard/Interpretation Application Date of Standard Application Date for the Group Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12) 1 January 2023 1 July 2023 Definition of Accounting Estimates (Amendments to IAS 8) 1 January 2023 1 July 2023 Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) 1 January 2023 1 July 2023 Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) 1 January 2024 1 July 2024 Lease Liability in a Sale and Leaseback (Amendments to IFRS 16) 1 January 2024 1 July 2024 Non-current Liabilities with Covenants (Amendments to IAS 1) 1 January 2024 1 July 2024 (d) Principles of Consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company. Control is achieved when the Company has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power. Subsidiaries are all those entities (including special purpose entities) over which the Company has the power to govern the financial and operating policies, so as to obtain benefits from its activities, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity. The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. Intercompany transactions and balances, income and expenses and profits and losses between Group companies, are eliminated. Investments in subsidiaries are accounted for at cost in the Statement of Financial Position of the Company. (e) Foreign Currencies (i) Functional and presentation currency The functional currency of each of the Group’s entities is measured using the currency of the primary economic environment in which that entity operates. The Company’s functional currency is Australian dollars. The Group’s financial statements are presented in United States dollars which is the Group’s presentation currency. United States dollars has been chosen as the Group’s presentation currency to better reflect the Groupʼs business activities in the United States and to enhance comparability with its industry peer group, the majority of which report in United States dollars. (ii) Transactions and balances Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined. Exchange differences arising on the translation of monetary items are recognised in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge. Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the income statement. (iii) Group companies The financial results and position of operations whose functional currency is different from the group’s presentation currency are translated as follows: • assets and liabilities are translated at year-end exchange rates prevailing at that reporting date; • income and expenses are translated at average exchange rates for the year; and • retained earnings are translated at the exchange rates prevailing at the date of the transaction. Exchange differences arising on translation into the presentation currency are transferred directly to the group’s foreign currency translation reserve in equity. These differences are recognised in profit or loss in the year in which the operation is disposed. (f) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of 3 months or less. (g) Trade and Other Receivables Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less allowance for expected credit losses, applying the simplified approach. If collection of the amounts is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. Trade receivables are generally due for settlement within 30 days and therefore are all classified as current. As the majority of receivables are short term in nature, their carrying amount is assumed to be the same as their fair value. (h) Prepayments Prepayments represent payments in advance of receipt of goods or services. The Group recognises a prepayment as an asset within other current and non-current assets when payment for goods or services has been made in advance of the Group obtaining a right to access those goods or services. Ther Group’s prepayments comprise of certain option payments made to Blacksand Technology, LLC as part of the Group’s exclusive option to purchase the assets of Blacksand. Upon exercise of the option, the prepaid amounts will transfer to the capital cost of the asset. These prepayments are assessed for indicators of impairment each year. If future economic benefits are no longer expected to occur, for example, if purchase of assets of Blacksand is no longer probable, and economic benefits cannot be derived from the prepayment in any other way, such as the absence of the ability to sell the option to another party or obtain a refund, the prepayment will be derecognised. (i) Property, Plant and Equipment All classes of property, plant and equipment are measured at cost. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, except for land which is not depreciated. Currently the Group only has plant and equipment which is depreciated over a period of 5 years. (j) Exploration and Development Expenditure Expenditure on exploration and evaluation is accounted for in accordance with the ‘area of interest’ method and with IFRS 6 Exploration for and Evaluation of Mineral Resources. Exploration and evaluation expenditure encompasses expenditures incurred by the Group in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource are demonstrable. For each area of interest, expenditure incurred in the acquisition of rights to explore is capitalised and recognised as an exploration and evaluation asset. This includes option payments made to landowners under the Group’s option agreements with local landowners which are considered part of the acquisition costs. Exploration and evaluation assets are measured at cost at recognition and are recorded as an asset if: (i) the rights to tenure of the area of interest are current; and (ii) at least one of the following conditions is also met: • the exploration and evaluation expenditures are expected to be recouped through successful development and exploitation of the area of interest, or alternatively, by its sale; and • exploration and evaluation activities in the area of interest have not at the reporting date reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area of interest are continuing. All other exploration and evaluation expenditures are expensed as incurred. Once the technical feasibility and commercial viability of a program or project has been demonstrated with a bankable feasibility study, the carrying amount of the exploration and evaluation expenditure in respect of the area of interest is reclassified as a “mine development property”. Where a decision is made to proceed with development, accumulated expenditure is tested for impairment and transferred to development properties, and then amortised over the life of the reserves associated with the area of interest once mining operations have commenced. Recoverability of the carrying amount of the exploration and evaluation assets is dependent on successful development and commercial exploitation, or alternatively, sale of the respective areas of interest. Impairment Capitalised exploration costs are reviewed each reporting date to establish whether an indication of impairment exists. If any such indication exists, the recoverable amount of the capitalised exploration costs is estimated to determine the extent of the impairment loss (if any). Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset. (k) Research and Development Expenditure Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Group can demonstrate: (a) the technical feasibility of completing the intangible asset so that the asset will be available for use or sale; (b) its intention to complete and its ability and intention to use or sell the asset; (c) how the asset will generate future economic benefits; (d) the availability of resources to complete the asset; and (e) the ability to measure reliably the expenditure during development. Development costs that do not meet these criteria are expensed as incurred. Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete, and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation is recorded in cost of sales. During the period of development, the asset is tested for impairment annually. (l) Trade and other payables These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method. The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature. (m) Provisions Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. (n) Interest income Interest income is recognised on a time proportionate basis that takes into account the effective yield on the financial asset. (o) Income Tax The income tax expense for the year is the tax payable on the current year’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses. Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised. Unrecognised deferred income tax assets are reassessed at each balance date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority. (p) Employee Entitlements Provision is made for the Group’s liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled wholly within 12 months have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs. (q) Earnings per Share Basic earnings per share (“EPS”) is calculated by dividing the net profit attributable to members of the Company for the reporting period, after excluding any costs of servicing equity, by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue. Diluted EPS is calculated by dividing the basic EPS earnings, adjusted by the after tax effect of financing costs associated with dilutive potential Ordinary Shares and the effect on revenues and expenses of conversion to Ordinary Shares associated with dilutive potential Ordinary Shares, by the weighted average number of Ordinary Shares and dilutive Ordinary Shares adjusted for any bonus issue. (r) Use and Revision of Accounting Estimates, Judgements and Assumptions The preparation of the financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year, or in the year of the revision and future years if the revision affects both current and future years. In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are described in the following note: • Functional currency (Note 1(e)); • Impairment of exploration and evaluation assets (Note 7); and • Share-based payments (Note 17). (s) Operating Segments An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors. Operating segments have been identified based on the information provided to the chief operating decision makers, being the board of directors. The group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects: • Nature of the products and services, • Nature of the production processes, • Type or class of customer for the products and services, • Methods used to distribute the products or provide the services, and if applicable, • Nature of the regulatory environment. Operating segments that meet the quantitative criteria as prescribed by IFRS 8 Operating Segments Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”. Currently, the Group has only one operating segment. (t) Impairment of Non-Financial Assets The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Group makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs of disposal and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount. In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. After such a reversal the depreciation charge is adjusted in future years to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life. (u) Fair Value Estimation The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes. The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities classified as fair value through other comprehensive income) is based on quoted market prices at the reporting date. The quoted market price used for financial assets held by the Group is the current bid price; the appropriate quoted market price for financial liabilities is the current ask price. The fair value of financial instruments that are not traded in an active market (for example, over the counter derivatives) is determined using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each balance date. Quoted market prices or dealer quotes for similar instruments are used for long-term debt instruments held. Other techniques, such as discounted cash flows, are used to determine fair value for the remaining financial instruments. The fair value of interest-rate swaps is calculated as the present value of the estimated future cash flows. The fair value of forward exchange contracts is determined using forward exchange market rates at the reporting date. The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments. (v) Issued and Unissued Capital Ordinary Shares and Performance Shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. (w) Dividends Provision is made for the amount of any dividend declared on or before the end of the year but not distributed at balance date. (x) Share-Based Payments Equity-settled share-based payments are provided to officers, employees, consultants and other advisors. These share-based payments are measured at the fair value of the equity instrument at the grant date. The fair value of options is estimated using the Black Scholes option valuation model. The fair value of performance rights that have market-based vesting conditions is estimated using a trinomial valuation model. The fair value of restricted stock units and performance rights that do not have market-based vesting conditions are estimated based on the underlying share price. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of equity instruments that will eventually vest. At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss over the remaining vesting period, with a corresponding adjustment to the share-based payments reserve. Equity-settled share-based payments may also be provided as consideration for the acquisition of assets. Where ordinary shares are issued, the transaction is recorded at fair value based on the quoted price of the ordinary shares at the date of issue. The acquisition is then recorded as an asset or expensed in accordance with accounting standards. (y) Leases The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognises right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. Lease liabilities At the commencement date of the lease, the Group recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercis

INCOME AND EXPENSES

INCOME AND EXPENSES	12 Months Ended
	Jun. 30, 2023
INCOME AND EXPENSES [Abstract]
INCOME AND EXPENSES	2. INCOME AND EXPENSES 2023 2022 July 20, 2020 to June 30, 2021 Note US$ US$ US$ Finance income Interest income 139,697 24,042 5,075 Net foreign exchange gain 354,772 377,003 - 494,469 401,045 5,075 Finance costs Interest expense (88,138 ) (45,541 ) (3,097 ) Other finance costs - (6,734 ) (4,395 ) (88,138 ) (52,275 ) (7,492 ) Other income and expenses Other income 60,470 - - Loss on derecognition of financial asset (250,000 ) - - Cost of listing on reverse acquisition - - (5,141,126 ) (189,530 ) - (5,141,126 ) Depreciation and amortisation Amortisation of right-of-use assets 8 (249,387 ) (119,706 ) (8,364 ) Depreciation of property, plant and equipment 8 (177,147 ) (33,728 ) (960 ) (426,534 ) (153,434 ) (9,324 ) Employee benefits expense Wages and salaries (4,714,673 ) (2,739,427 ) (509,474 ) Employee benefits (808,717 ) (376,974 ) (44,325 ) Post-employment benefits (134,074 ) (67,496 ) (8,929 ) Share-based payment expenses (2,589,413 ) (8,340,328 ) (4,084,764 ) (8,246,877 ) (11,524,225 ) (4,647,492 )

INCOME TAX

INCOME TAX	12 Months Ended
	Jun. 30, 2023
INCOME TAX [Abstract]
INCOME TAX	3. INCOME TAX 2023 2022 July 20, 2020 to June 30, 2021 Note US$ US$ US$ Recognised in profit or loss Current income tax: Current income tax benefit in respect of the current year - - - Deferred income tax: Origination and reversal of temporary differences - - - Income tax expense reported in profit or loss - - - Reconciliation between tax expense and accounting loss before income tax Accounting loss before income tax (17,444,754 ) (21,521,237 ) (13,230,837 ) At the Australian income tax rate of 30 (5,233,426 ) (6,456,371 ) (3,969,251 ) Effect of lower income tax rate in the United States 488,952 433,351 124,391 Expenditure not allowable for income tax purposes 870,584 2,502,099 2,942,127 Exchange differences 5,329 30,731 (5,365 ) Adjustments in respect of deferred tax of previous years (182,314 ) 174,258 - Effect of deferred tax assets not brought to account 4,050,875 3,315,932 908,098 Income tax expense reported in profit or loss - - - Deferred tax assets and liabilities Deferred tax liabilities: Right-of-use assets 305,000 121,755 142,128 Deferred tax assets used to offset deferred tax liabilities (305,000 ) (121,755 ) (142,128 ) - - - Deferred tax assets: Accrued expenditures 139,113 22,500 53,997 Provisions 21,956 12,125 2,893 Lease liabilities 246,832 132,393 142,695 Capital allowances 3,241,541 2,535,077 - Tax losses available to offset against future taxable income 5,361,043 2,053,718 1,260,669 Deferred tax assets used to offset deferred tax liabilities (305,000 ) (121,755 ) (142,128 ) Deferred tax assets acquired on reverse acquisition not brought to account (1) - - (410,028 ) Other deferred tax assets not brought to account (1) (8,705,485 ) (4,634,058 ) (908,098 ) - - - Notes: (1) The benefit of deferred tax assets not brought to account will only be subsequently recognised if: (a) future assessable income is derived of a nature and of an amount sufficient to enable the benefit to be realised; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realising the benefit.

DIVIDENDS PAID OR PROVIDED FOR

DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES	12 Months Ended
	Jun. 30, 2023
DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES [Abstract]
DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES	4. DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES No dividends have been paid or proposed for the year ended June 30, 2023 (2022: nil nil

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Jun. 30, 2023
CASH AND CASH EQUIVALENTS [Abstract]
CASH AND CASH EQUIVALENTS	5. CASH AND CASH EQUIVALENTS 2023 2022 July 20, 2020 to June 30, 2021 US$ US$ US$ Cash at bank and on hand 11,937,941 5,672,551 1,697,904 11,937,941 5,672,551 1,697,904 Reconciliation of loss before income tax to net cash flows from operations Loss for the year (17,444,754 ) (21,521,237 ) (13,230,837 ) Adjustment for non-cash income and expense items Share-based payments expense 2,589,413 8,340,328 4,084,764 Amortisation of right-of-use assets 249,387 119,706 8,364 Depreciation of property, plant and equipment 177,147 33,728 960 Net foreign exchange loss/(gain) (354,772 ) (377,003 ) - Loss on derecognition of financial asset 250,000 - - Lease modifications - (2,112 ) - Cost of listing on reverse acquisition - - 5,141,126 Changes in assets and liabilities Increase in receivables and prepayments (650,067 ) (98,797 ) (34,405 ) (Decrease)/increase in payables and provisions (680,748 ) 1,371,310 472,003 Net cash outflow from operating activities (15,864,394 ) (12,134,077 ) (3,558,025 )

PREPAYMENTS

PREPAYMENTS	12 Months Ended
	Jun. 30, 2023
PREPAYMENTS [Abstract]
PREPAYMENTS	6. PREPAYMENTS 2023 2022 US$ US$ Current Other prepayments 588,395 144,183 Total current prepayments 588,395 144,183 Non-current Blacksand option prepayments (1) 3,000,000 - Total non-current prepayments 3,000,000 - Total prepayments 3,588,395 144,183 Notes: (1) At June 30, 2023, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. The Group can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable by January 2023, July 2023, January 2024 and July 2024). These prepayments represent the first two option payments to Blacksand, paid in December 2022 and June 2023. Refer Note 21 for further details.

EXPLORATION AND EVALUATION ASSE

EXPLORATION AND EVALUATION ASSETS	12 Months Ended
	Jun. 30, 2023
EXPLORATION AND EVALUATION ASSETS [Abstract]
EXPLORATION AND EVALUATION ASSETS	7. EXPLORATION AND EVALUATION ASSETS Titan Project (1) US$ 2023 Carrying amount at July 1, 2022 2,431,229 Additions 627,792 Carrying amount at June 30, 2023 (2) 3,059,021 2022 Carrying amount at July 1, 2021 504,750 Additions 1,926,479 Carrying amount at June 30, 2022 (2) 2,431,229 Notes: (1) At June 30, 2023, the Titan Project comprised of approximately 11,071 acres of surface and associated mineral rights in Tennessee prospective for heavy mineral sands, including titanium, rare earth minerals, high grade silica sand, and zircon, of which approximately 453 acres are owned and approximately 10,618 acres are subject to exclusive option agreements. These exclusive option agreements, upon exercise, allow the Group to lease, or in some cases purchase, the surface property and associated mineral rights. (2) The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Jun. 30, 2023
PROPERTY, PLANT AND EQUIPMENT [Abstract]
PROPERTY, PLANT AND EQUIPMENT	8. PROPERTY, PLANT AND EQUIPMENT Plant and Right-of-use assets Total US$ US$ US$ 2023 Carrying amount at July 1, 2022 922,118 465,868 1,387,986 Additions 2,077,794 950,537 3,028,331 Depreciation and amortization (177,147 ) (249,387 ) (426,534 ) Carrying amount at June 30, 2023 2,822,765 1,167,018 3,989,783 - at cost 3,034,599 1,543,876 4,578,475 - accumulated depreciation (211,834 ) (376,858 ) (588,692 ) 2022 Carrying amount at July 1, 2021 65,858 473,761 539,619 Additions 889,988 140,188 1,030,176 Modifications - (28,375 ) (28,375 ) Depreciation and amortization (33,728 ) (119,706 ) (153,434 ) Carrying amount at June 30, 2022 922,118 465,868 1,387,986 - at cost 956,805 593,339 1,550,144 - accumulated depreciation (34,687 ) (127,471 ) (162,158 )

TRADE AND OTHER PAYABLES

TRADE AND OTHER PAYABLES	12 Months Ended
	Jun. 30, 2023
TRADE AND OTHER PAYABLES [Abstract]
TRADE AND OTHER PAYABLES	9. TRADE AND OTHER PAYABLES 2023 2022 US$ US$ Current Trade payables 711,011 1,677,757 Accruals 455,241 196,450 Payroll liabilities 14,732 25,141 Total trade and other payables 1,180,984 1,899,348

LOANS AND BORROWINGS

LOANS AND BORROWINGS	12 Months Ended
	Jun. 30, 2023
LOANS AND BORROWINGS [Abstract]
LOANS AND BORROWINGS	10. LOANS AND BORROWINGS 2023 2022 US$ US$ Current Lease liabilities 376,655 128,653 Other loans and borrowings 5,971 5,594 Total current loans and borrowings 382,626 134,247 Non-current Lease liabilities 567,796 377,920 Other loans and borrowings 24,892 30,863 Total non-current loans and borrowings 592,688 408,783 Total loans and borrowings 975,314 543,030 (a) Reconciliation Balance at Additions Repayments Balance at June 30, 2023 US$ US$ US$ US$ Lease liabilities 506,573 950,538 (512,660 ) 944,451 Other loans and borrowings 36,457 - (5,594 ) 30,863 Total loans and borrowings 543,030 950,538 (518,254 ) 975,314

LEASES

LEASES	12 Months Ended
	Jun. 30, 2023
LEASES [Abstract]
LEASES	11. LEASES The Group leases office premises, vehicles and plant and equipment in the United States. The carrying amounts of right-of-use assets (included under property, plant and equipment) and the movements during the year are in Note 8. The carrying amounts of lease liabilities (included under financial liabilities) and the movements during the year are set out in Note 10. The following are the amounts recognised in profit or loss in respect of leases: 2023 2022 Note US$ US$ Amortisation of right-of-use assets 8 (249,387 ) (119,706 ) Interest expense on lease liabilities (78,040 ) (44,512 ) Net amount recognised in profit or loss (327,427 ) (164,218 )

CONTRIBUTED EQUITY

CONTRIBUTED EQUITY	12 Months Ended
	Jun. 30, 2023
CONTRIBUTED EQUITY [Abstract]
CONTRIBUTED EQUITY	12. CONTRIBUTED EQUITY 2023 2022 Note US$ US$ Issued capital 193,493,973 140,288,491 12(a) 58,764,248 29,782,268 (a) Movements in issued capital Number of Ordinary Shares Number of Performance Shares Number of Performance Shares US$ 2023 Opening balance at July 1, 2022 140,288,491 19,800,000 19,800,000 29,782,268 Issue of shares – share placements 50,000,000 - - 29,637,300 Issue of shares – exercise of options 2,102,363 - - 477,156 Issue of shares – conversion of RSUs 200,001 - - 167,487 Issue of shares – conversion of performance rights 215,495 - - 216,007 Issue of shares to consultant 687,623 - - 350,000 Share issue costs - - - (1,865,970 ) Closing balance at June 30, 2023 193,493,973 19,800,000 19,800,000 58,764,248 2022 Opening balance at July 1, 2021 105,105,787 19,800,000 19,800,000 10,255,369 Issue of shares – share placements 20,000,000 - - 17,604,000 Issue of shares – exercise of options 15,182,704 - - 2,353,704 Share issue costs - - - (430,805 ) Closing balance at June 30, 2022 140,288,491 19,800,000 19,800,000 29,782,268 (b) Rights attaching to Ordinary Shares The rights attaching to fully paid ordinary shares (“Ordinary Shares”) arise from a combination of the Company’s Constitution, statute and general law: • Shares - The issue of shares in the capital of the Company and options over unissued shares by the Company is under the control of the directors, subject to the Corporations Act 2001, ASX Listing Rules and any rights attached to any special class of shares. • Meetings of Members - Directors may call a meeting of members whenever they think fit. Members may call a meeting as provided by the Corporations Act 2001.The Constitution contains provisions prescribing the content requirements of notices of meetings of members and all members are entitled to a notice of meeting. A meeting may be held in two or more places linked together by audio-visual communication devices. A quorum for a meeting of members is 2 shareholders. The Company holds annual general meetings in accordance with the Corporations Act 2001 and the Listing Rules. • Voting - Subject to any rights or restrictions at the time being attached to any shares or class of shares of the Company, each member of the Company is entitled to receive notice of, attend and vote at a general meeting. Resolutions of members will be decided by a show of hands unless a poll is demanded. On a show of hands each eligible voter present has one vote. However, where a person present at a general meeting represents personally or by proxy, attorney or representative more than one member, on a show of hands the person is entitled to one vote only despite the number of members the person represents. On a poll each eligible member has one vote for each fully paid share held and a fraction of a vote for each partly paid share determined by the amount paid up on that share. • Changes to the Constitution - The Company’s Constitution can only be amended by a special resolution passed by at least three quarters of the members present and voting at a general meeting of the Company. At least 28 days’ written notice specifying the intention to propose the resolution as a special resolution must be given. • Listing Rules - Provided the Company remains admitted to the Official List, then despite anything in its Constitution, no act may be done that is prohibited by the Listing Rules, and authority is given for acts required to be done by the Listing Rules. The Company’s Constitution will be deemed to comply with the Listing Rules as amended from time to time. (c) Rights attaching to Performance Shares Performance Shares comprise 19,800,000 Class A and 19,800,000 Class B Performance Shares issued in relation to the acquisition of Hyperion Metals (Australia) Pty Ltd and are issued based upon the following terms and conditions: • The Performance Shareholders are not entitled to a dividend; • The Performance Shares are not transferable; • The Performance Shareholders shall have no right to vote, subject to the Corporations Act; • The Performance Shares will convert into Ordinary Shares as follows: o Each Class A Performance Share will convert into one (1) Ordinary Share upon completion of a positive pre-feasibility study (prepared in accordance with the JORC Code and independently verified by a Competent Person) for heavy mineral sands mining and processing on any of the Titan Project area which demonstrates a net present value of at least A$200,000,000 before September 17, 2024 (the “ Pre-Feasibility Study Milestone o Each Class B Performance Share will convert into one (1) Ordinary Share upon the commencement of commercial production from the Titan Project area before September 17, 2025 (the “ First Production Milestone o All Performance Shares shall automatically convert into Ordinary Shares upon the occurrence of certain change of control events; and o To the extent that any Performance Shares have not converted into Ordinary Shares by the applicable expiry date, all such Performance Shares for each holder will automatically lapse and be combined into one single Performance Share that will then convert into one single Ordinary Share. If the Class A Performance Shares have not converted into Ordinary Shares by the applicable expiry date, then the 19,800,000 Class A Performance Shares will convert into 30 Ordinary Shares. If the Class B Performance Shares have not converted into Ordinary Shares by the applicable expiry date, then the 19,800,000 Class B Performance Shares will convert into 30 Ordinary Shares. If neither the Class A Performance Shares nor the Class B Performance Shares have converted into Ordinary Shares by the applicable expiry date, then the 39,600,000 Performance Shares will convert into 60 Ordinary Shares. • The Ordinary Shares issued on conversion of any Performance Share will rank equally with and confer rights identical with all other Ordinary Shares then on issue and application will be made by the Company to ASX for official quotation of the Ordinary Shares upon the date of conversion. • The Company shall allot and issue Ordinary Shares immediately upon conversion of the Performance Shares for no consideration and shall record the allotment and issue in the manner required by the Corporations Act. • The Performance Shares are unquoted. No application for quotation of the Performance Shares will be made by the Company.

RESERVES

RESERVES	12 Months Ended
	Jun. 30, 2023
RESERVES [Abstract]
RESERVES	13. RESERVES 2023 2022 Note US$ US$ Share-based payments reserve 13(b ) 15,004,052 12,985,856 Foreign currency translation reserve 13(f ) (1,008,244 ) (596,331 ) 13,995,808 12,389,525 (a) Nature and purpose of reserves (i) Share-based payments reserve The share-based payments reserve is used to record the fair value of Unlisted Options, Restricted Stock Units and Performance Rights issued by the Group. (ii) Foreign currency translation reserve Exchange differences arising on translation of entities whose functional currency is different to the Group’s presentation currency are taken to the foreign currency translation reserve, as described in Note 1(e). (b) Movements in share-based payments reserve during the year Number of Listed Number of Unlisted Options Number of Performance Rights No. of Restricted Stock Units US$ 2023 Opening balance at July 1, 2022 - 23,824,000 27,620,000 600,000 12,985,856 Grant of employee incentive securities - 424,372 1,535,000 424,372 - Grant of options to financial advisor - 1,000,000 - - 354,788 Exercise of options - (2,237,000 ) - - (192,511 ) Conversion of RSUs - - (329,000 ) - (167,487 ) Conversion of performance rights - - - (200,001 ) (216,007 ) Issue of shares to a consultant - - - - (350,000 ) Lapse of employee incentive securities - - (80,000 ) - - Share-based payment expense - - - - 2,589,413 Closing balance at June 30, 2023 - 23,011,372 28,746,000 824,371 15,004,052 2022 Opening balance at July 1,2021 12,624,214 25,800,000 16,325,000 - 4,738,007 Grant of employee incentive securities - 600,000 11,295,000 600,000 - Exercise of options (12,606,704 ) (2,576,000 ) - - (92,479 ) Expiry of options (17,510 ) - - - - Share-based payment expense - - - - 8,340,328 Closing balance at June 30, 2022 - 23,824,000 27,620,000 600,000 12,985,856 Notes: (1) For details on the valuation of Unlisted Options, Performanc e Rights and Restricted Stock Units, (c) Terms and conditions of Unlisted Options Unlisted Options granted as share-based payments have the following terms and conditions: • Each Unlisted Option entitles the holder to the right to subscribe for one Share upon the exercise of each Unlisted Option; • The Unlisted Options outstanding at the end of the financial year have the following exercise prices and expiry dates: o 2,550,000 Unlisted Options exercisable at A$0.20 each on or before December 31, 2023; o 3,975,000 Unlisted Options exercisable at A$0.20 each on or before December 1, 2025; o 4,000,000 Class A Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025; o 4,000,000 Class B Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025; o 4,612,000 Unlisted Options exercisable at A$0.25 each on or before December 31, 2023; o 975,000 Unlisted Options exercisable at A$0.45 each on or before December 31, 2023; o 875,000 Unlisted Options exercisable at A$0.55 each on or before December 31, 2023; o 424,372 Unlisted Options exercisable at A$0.87 each on or before December 5, 2026; o 1,000,000 Unlisted Options exercisable at A$1.10 each on or before September 14, 2025; and o 600,000 Unlisted Options exercisable at A$1.33 each on or before September 9, 2025. • The Unlisted Options are exercisable at any time prior to the Expiry Date, subject to vesting conditions being satisfied (if applicable); • Shares issued on exercise of the Unlisted Options rank equally with the then Shares of the Company; • Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Unlisted Options; • If there is any reconstruction of the issued share capital of the Company, the rights of the Unlisted Option holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and • No application for quotation of the Unlisted Options will be made by the Company. (d) Terms and conditions of Performance Rights Performance Rights granted as share-based payments have the following terms and conditions: • Each Performance Right automatically converts into one Share upon vesting of the Performance Right; • Each Performance Right is subject to performance conditions (as determined by the Board from time to time) which must be satisfied in order for the Performance Right to vest; • The Performance Rights outstanding at the end of the financial year have the following performance conditions and expiry dates: o 6,101,665 Performance Rights that vest upon achieving a 30-day VWAP of A$2.00 per share (175,000 expiring April 23, 2024, 25,000 expiring December 22, 2024, 150,000 expiring March 1, 2026, 5,701,665 expiring April 23, 2026, and 50,000 expiring December 22, 2026); o 7,661,667 Performance Rights that vest upon achieving a 30-day VWAP of A$3.00 per share (275,000 expiring April 23, 2024, 25,000 expiring December 22, 2025, 150,000 expiring March 1, 2026, 7,111,667 expiring April 23, 2026, and 100,000 expiring December 22, 2026); o 12,746,668 Performance Rights that vest upon achieving a 30-day VWAP of A$4.00 per share (125,000 Performance Rights expiring April 23, 2024, 1,000,000 Performance Rights expiring April 6, 2025, 50,000 expiring December 22, 2025, 150,000 expiring March 1, 2026, 11,246,668 expiring April 23, 2026, and 175,000 expiring December 22, 2026); and o 2,236,000 Performance Rights that vest upon achieving various (non-market based) performance conditions (1,000,000 expiring April 6, 2025, 261,000 expiring December 22, 2025, 55,000 200,000 265,000 55,000 400,000 • Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the Performance Rights; • If there is any reconstruction of the issued share capital of the Company, the rights of the Performance Right holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; • No application for quotation of the Performance Rights will be made by the Company; and • Without approval of the Board, Performance Rights may not be transferred, assigned or novated, except, upon death, a participant’s legal personal representative may elect to be registered as the new holder of such Performance Rights and exercise any rights in respect of them. (e) Terms and conditions of Restricted Stock Units Restricted stock units (“RSUs”) granted as share-based payments have the following terms and conditions: • Each RSU automatically converts into one Share upon vesting of the RSU; • Each RSU is subject to service based performance conditions (as determined by the Board from time to time) which must be satisfied in order for the RSU to vest; • The RSUs outstanding at the end of the financial year have the following conditions and expiry dates: o 399,999 RSUs that vest upon achieving various service-based conditions, expiring September 9, 2025; and o 424,372 RSUs that vest upon achieving various service-based conditions, expiring December 5, 2026. • Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the RSUs; • If there is any reconstruction of the issued share capital of the Company, the rights of the RSU holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; • No application for quotation of the RSUs will be made by the Company; and • Without approval of the Board, RSUs may not be transferred, assigned or novated, except, upon death, a participant’s legal personal representative may elect to be registered as the new holder of such RSUs and exercise any rights in respect of them. (f) Movements in foreign currency translation reserve during the year 2023 2022 US$ US$ Balance at start of year (596,331 ) (2,419 ) Exchange differences arising on translation into presentation currency (411,913 ) (593,912 ) Balance at June 30 (1,008,244 ) (596,331 )

ACCUMULATED LOSSES

ACCUMULATED LOSSES	12 Months Ended
	Jun. 30, 2023
ACCUMULATED LOSSES [Abstract]
ACCUMULATED LOSSES	14 ACCUMULATED LOSSES 2023 2022 US$ US$ Balance at start of year (34,752,074 ) (13,230,837 ) Net loss for the year (17,444,754 ) (21,521,237 ) Balance at June 30 (52,196,828 ) (34,752,074 )

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Jun. 30, 2023
LOSS PER SHARE [Abstract]
LOSS PER SHARE	15. LOSS PER SHARE 2023 2022 US$ July 20, 2020 to June 30, 2021 Basic loss per share (1) (0.11 ) (0.16 ) (0.19 ) Diluted loss per share (1) (0.11 ) (0.16 ) (0.19 ) Notes: (1) Basic and diluted loss per share for the comparative period from July 20, 2020 to June 30, 2021 have been revised. Refer to Note 1(a) for further information The following reflects the income and share data used in the calculations of basic earnings per share: 2023 2022 US$ July 20, 2020 to June 30, 2021 Net loss (17,444,754 ) (21,521,237 ) (13,230,837 ) Net loss used in calculating basic and dilutive earnings per share (17,444,754 ) (21,521,237 ) (13,230,837 ) Number of Ordinary Shares 2023 Number of Ordinary Shares 2022 Number of Ordinary Shares 2021 Weighted average number of Ordinary Shares used in calculating basic and dilutive earnings per share 168,029,357 134,609,413 68,798,762 (a) Anti-Dilutive Securities As at June 30, 2023, 23,011,372 Unlisted Options, 28,746,000 Performance Rights, 824,371 Restricted Stock Units and 39,600,000 Performance Shares, which together represent 92,181,743 potential Ordinary Shares (2022: 91,644,000) (2021: 94,349,214), were not included in the calculation of diluted loss per share because they are considered anti-dilutive as they would decrease the loss per share for the periods presented. (b) Conversions, Calls, Subscriptions or Issues after June 30, 2023 Subsequent to June 30, 2023, the Company has: • issued 1,225,000 ordinary shares pursuant to the exercise of unlisted options; • issued 50,000 performance rights to employees of the Group; and • cancelled 80,000 performance rights upon forfeiture. Other than as above,

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Jun. 30, 2023
RELATED PARTIES [Abstract]
RELATED PARTIES	16. RELATED PARTIES (a) Subsidiaries Country of Equity Interest 2023 2022 2021 % Hyperion Metals (Australia) Pty Ltd Australia 100 100 100 IperionX Critical Minerals LLC United States 100 100 100 IperionX Technology LLC United States 100 100 100 IperionX Inc. United States 100 100 - Calatos Pty Ltd LLC United States 100 100 100 (b) Ultimate Parent IperionX Limited is the ultimate parent of the Group. (c) Key Management Personnel The aggregate compensation made to Key Management Personnel of the Group is set out below: 2023 2022 July 20, 2020 to June 30, 2021 Short-term employee benefits 2,109,813 1,503,275 275,246 Post-employment benefits 47,502 25,114 6,079 Share-based payments 1,650,382 7,146,121 3,681,159 Total compensation 3,807,697 8,674,510 3,962,484 No loans were provided to or received from Key Management Personnel during the year ended June 30, 2023 (2022: nil nil (d) Other transactions with Related Parties Performance Industries, Inc., a Company associated with Mr. Scott Sparks, Chief Operating Officer of the Company, was paid US$145,055 during the 2023 financial year for the provision engineering and construction services to the Group. The Company considers that the services provided by Performance Industries, Inc. were provided on an arm’s length basis. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.

SHARE-BASED PAYMENTS

SHARE-BASED PAYMENTS	12 Months Ended
	Jun. 30, 2023
SHARE-BASED PAYMENTS [Abstract]
SHARE-BASED PAYMENTS	17. SHARE-BASED PAYMENTS (a) Recognised share-based payment expense From time to time, the Group grants ordinary shares (“Shares”), unlisted options (“Options”), performance rights (“Rights”), and restricted stock units (“RSUs”) to officers, employees, consultants and other key advisors as part of remuneration and incentive arrangements. The number of Shares, Options, Rights, and RSUs granted, and the terms of the options or rights granted are determined by the Board. Shareholder approval is sought where required. During fiscal 2023, fiscal 2022, and fiscal 2021 the following equity-settled share-based payments have been recognised: 2023 2022 July 20, 2020 to June 30, 2021 Expense arising from staff remuneration arrangements (2,589,413 ) (8,340,328 ) (4,084,764 ) Expense arising from cost of listing on reverse acquisition - — (5,141,126 ) Total expense arising from equity-settled share-based payment transactions (2,589,413 ) (8,340,328 ) (9,225,890 ) (b) Summary of securities granted as share-based payments The following table illustrates the number and weighted average exercise prices (“WAEP”) of Options, Rights, and RSUs granted as share-based payments during fiscal 2023, fiscal 2022, and fiscal 2021 (excluding Shares): 2023 2023 2022 2022 2021 2021 Outstanding at beginning of year 52,044,000 A$0.12 54,749,214 A$0.19 - - Options granted during the year 1,424,372 A$1.03 600,000 A$1.33 9,150,000 A$0.31 Rights granted during the year 1,535,000 - 11,295,000 - 16,325,000 - RSUs granted during the year 424,372 - 600,000 - - - Listed Options exercised during the year - - (12,606,704 ) (A$0.20 ) (3,069,120 ) (A$0.20 ) Options exercised during the year (2,237,000 ) (A$0.26 ) (2,576,000 ) (A$0.22 ) (1,350,000 ) (A$0.24 ) Rights converted during the year (329,000 ) - - - (2,000,000 ) - RSUs converted during the year (200,001 ) - - - - - Listed Options expired during the year - - (17,510 ) (A$0.20 ) - - Rights lapsed during the year (80,000 ) - - - - - Recognition of legal acquirer Listed Options - - - - 15,693,334 A$0.20 Recognition of legal acquirer Options - - - - 5,000,000 A$0.20 Recognition of legal acquirer Rights - - - - 2,000,000 - Options granted to vendors of legal acquiree - - - - 13,000,000 A$0.20 Outstanding at end of year 52,581,743 (A$0.14 ) 52,044,000 A$0.12 54,749,214 A$0.19 The following Options, Rights and RSUs were granted as share-based payments during fiscal 2023, fiscal 2022, and fiscal 2021: 2023 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Options 1,000,000 14-Sep-22 14-Sep-25 A$1.10 - $ 0.519 Series 2 Options 424,372 25-Nov-22 05-Dec-26 A$0.87 - $ 0.424 Series 3 RSUs 424,372 25-Nov-22 05-Dec-26 - - $ 0.740 Series 4 Rights 400,000 8-Aug-22 23-Apr-26 - A$3.00 $ 0.354 Series 5 Rights 400,000 8-Aug-22 23-Apr-26 - A$4.00 $ 0.293 Series 6 Rights 200,000 8-Aug-22 23-Apr-26 - - $ 0.675 Series 7 Rights 10,000 6-Sep-22 23-Apr-26 - A$2.00 $ 0.617 Series 8 Rights 15,000 6-Sep-22 23-Apr-26 - A$3.00 $ 0.496 Series 9 Rights 35,000 6-Sep-22 23-Apr-26 - A$4.00 $ 0.428 Series 10 Rights 10,000 6-Jun-22 23-Apr-26 - A$2.00 $ 0.556 Series 11 Rights 15,000 6-Jun-22 23-Apr-26 - A$3.00 $ 0.460 Series 12 Rights 20,000 6-Jun-22 23-Apr-26 - A$4.00 $ 0.390 Series 13 Rights 10,000 8-Jun-22 31-Dec-24 - - $ 0.780 Series 14 Rights 10,000 8-Jun-22 31-Dec-25 - - $ 0.780 Series 15 Rights 10,000 8-Jun-22 31-Dec-26 - - $ 0.780 Series 16 Shares 687,623 20-Dec-22 - - - $ 0.775 Series 17 Rights 400,000 1-Feb-23 31-Jan-27 - - $ 0.880 Series 18 Rights 25,000 16-Mar-23 23-Apr-26 - A$3.00 $ 0.286 Series 19 Rights 25,000 16-Mar-23 23-Apr-26 - A$4.00 $ 0.219 Series 20 Rights 175,000 1-Apr-23 23-Apr-26 - A$3.00 $ 0.321 Series 21 Rights 175,000 1-Apr-23 23-Apr-26 - A$4.00 $ 0.247 2022 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Rights 200,000 19-Jul-21 22-Dec-24 - - $ 0.930 Series 2 Rights 200,000 19-Jul-21 22-Dec-25 - - $ 0.930 Series 3 Rights 200,000 19-Jul-21 22-Dec-26 - - $ 0.930 Series 4 Rights 25,000 19-Jul-21 23-Apr-26 - $ 4.00 $ 0.710 Series 5 Rights 25,000 19-Jul-21 23-Apr-24 - $ 2.00 $ 0.699 Series 6 Rights 25,000 19-Jul-21 23-Apr-24 - $ 3.00 $ 0.591 Series 7 Rights 1,000,000 01-Sep-21 23-Apr-26 - $ 3.00 $ 1.195 Series 8 Rights 1,000,000 01-Sep-21 23-Apr-26 - $ 4.00 $ 1.131 Series 9 RSUs 600,000 13-Sep-21 09-Sep-25 - - $ 1.170 Series 10 Options 600,000 13-Sep-21 09-Sep-25 $ 1.33 - $ 0.775 Series 11 Rights 4,000 11-Oct-21 22-Dec-24 - - $ 1.100 Series 12 Rights 6,000 11-Oct-21 22-Dec-25 - - $ 1.100 Series 13 Rights 10,000 11-Oct-21 22-Dec-26 - - $ 1.100 Series 14 Rights 40,000 12-Oct-21 22-Dec-24 - - $ 1.070 Series 15 Rights 40,000 12-Oct-21 22-Dec-25 - - $ 1.070 2022 (Continued) Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 16 Rights 40,000 12-Oct-21 22-Dec-26 - - $ 1.070 Series 17 Rights 225,000 14-Oct-21 23-Apr-26 - $ 4.00 $ 0.801 Series 18 Rights 25,000 14-Oct-21 23-Apr-24 - $ 2.00 $ 0.790 Series 19 Rights 125,000 14-Oct-21 23-Apr-24 - $ 3.00 $ 0.663 Series 20 Rights 15,000 08-Nov-21 22-Dec-24 - - $ 0.955 Series 21 Rights 15,000 08-Nov-21 22-Dec-25 - - $ 0.955 Series 22 Rights 15,000 08-Nov-21 22-Dec-26 - - $ 0.955 Series 23 Rights 30,000 15-Nov-21 31-Dec-24 - - $ 0.990 Series 24 Rights 30,000 15-Nov-21 31-Dec-25 - - $ 0.990 Series 25 Rights 30,000 15-Nov-21 31-Dec-26 - - $ 0.990 Series 26 Rights 3,500,000 25-Nov-21 23-Apr-26 - $ 4.00 $ 0.644 Series 27 Rights 250,000 06-Dec-21 23-Apr-26 - $ 2.00 $ 0.703 Series 28 Rights 250,000 06-Dec-21 23-Apr-26 - $ 3.00 $ 0.642 Series 29 Rights 500,000 06-Dec-21 23-Apr-26 - $ 4.00 $ 0.594 Series 30 Rights 50,000 15-Dec-21 22-Dec-26 - - $ 0.752 Series 31 Rights 314,998 15-Dec-21 23-Apr-26 - $ 2.00 $ 0.728 Series 32 Rights 100,000 15-Dec-21 22-Dec-26 - - $ 0.700 Series 33 Rights 315,001 15-Dec-21 23-Apr-26 - $ 3.00 $ 0.665 Series 34 Rights 150,000 15-Dec-21 22-Dec-26 - - $ 0.658 Series 35 Rights 325,001 15-Dec-21 23-Apr-26 - $ 4.00 $ 0.616 Series 36 Rights 30,000 01-Jan-22 31-Dec-24 - - $ 0.910 Series 37 Rights 30,000 01-Jan-22 31-Dec-25 - - $ 0.910 Series 38 Rights 30,000 01-Jan-22 31-Dec-26 - - $ 0.910 Series 39 Rights 50,000 01-Jan-22 22-Dec-25 - $ 4.00 $ 0.634 Series 40 Rights 25,000 31-Jan-22 22-Dec-26 - $ 4.00 $ 0.695 Series 41 Rights 25,000 31-Jan-22 22-Dec-24 - $ 2.00 $ 0.684 Series 42 Rights 25,000 31-Jan-22 22-Dec-25 - $ 3.00 $ 0.677 Series 43 Rights 1,000,000 29-Mar-22 06-Apr-25 - - $ 1.235 Series 44 Rights 1,000,000 29-Mar-22 06-Apr-25 - $ 4.00 $ 0.840 2021 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Options 7,000,000 01-Dec-20 31-Dec-23 $ 0.25 - $ 0.163 Series 2 Options 5,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 3 Options 4,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 4 Options 4,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 5 Options 5,000,000 01-Dec-20 31-Dec-23 $ 0.20 - $ 0.174 Series 6 Rights 150,000 03-Mar-21 01-Mar-26 - $ 2.00 $ 0.694 Series 7 Rights 150,000 03-Mar-21 01-Mar-26 - $ 3.00 $ 0.643 Series 8 Rights 150,000 03-Mar-21 01-Mar-26 - $ 4.00 $ 0.602 Series 9 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 2.00 $ 0.745 Series 10 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 3.00 $ 0.693 Series 11 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 4.00 $ 0.651 Series 12 Options 875,000 14-Apr-21 31-Dec-23 $ 0.45 - $ 0.605 Series 13 Options 875,000 14-Apr-21 31-Dec-23 $ 0.55 - $ 0.575 Series 14 Rights 125,000 15-Apr-21 23-Apr-24 - $ 2.00 $ 0.599 Series 15 Rights 125,000 15-Apr-21 23-Apr-24 - $ 3.00 $ 0.510 Series 16 Rights 125,000 15-Apr-21 23-Apr-24 - $ 4.00 $ 0.445 Series 17 Rights 2,875,000 15-Apr-21 23-Apr-26 - $ 2.00 $ 0.705 Series 18 Rights 2,875,000 15-Apr-21 23-Apr-26 - $ 3.00 $ 0.654 Series 19 Rights 2,975,000 15-Apr-21 23-Apr-26 - $ 4.00 $ 0.613 Series 20 Options 200,000 15-Apr-21 31-Dec-23 $ 0.45 - $ 0.570 Series 21 Options 200,000 15-Apr-21 31-Dec-23 $ 0.55 - $ 0.540 Series 22 Rights 258,333 22-Jun-21 23-Apr-26 - $ 2.00 $ 0.821 Series 23 Rights 258,333 22-Jun-21 23-Apr-26 - $ 3.00 $ 0.763 Series 24 Rights 258,334 22-Jun-21 23-Apr-26 - $ 4.00 $ 0.716 (c) Weighted Average Remaining Contractual Life At June 30, 2023, the weighted average remaining contractual life of Unlisted Options, Performance Rights and Restricted Stock Units on issue that had been granted as share-based payments was 2.27 years (2022: 3.17 years) (2021: 3.16 years). (d) Weighted Average Fair Value The weighted average fair value of Unlisted Options, Performance Rights and Restricted Stock Units granted as share-based payments by the Group during the year ended June 30, 2023 was A$0.51 (2022: A$0.85) (2021: A$0.53). (e) Range of Exercise Prices At June 30, 2023, the range of exercise prices of Unlisted Options on issue that had been granted as share-based payments was A$0.20 to A$1.33 (2022: A$0.20 to A$0.1.33) (2021: A$0.20 to A$0.55). (f) Option, Right and RSU Pricing Models The fair value of granted Options is estimated as at the date of grant using the Black Scholes option valuation model taking into account the terms and conditions upon which the Unlisted Options were granted. The fair value of granted Rights that have market-based vesting conditions is estimated as at the date of grant using a trinomial valuation model taking into account the market-based vesting criteria upon which the Rights were granted. The fair value of granted RSUs and Rights that do not have market-based vesting conditions are estimated as at the date of grant based on the underlying share price. The tables below list the inputs to the valuation models used for Options, Rights, and RSUs granted by the Group during fiscal 2023 and fiscal 2022: 2023 2022 2021 Options RSUs and Rights that don’t have market-based vesting conditions Rights that have market-based vesting conditions Options RSUs and Rights that don’t have market-based vesting conditions Rights that have market-based vesting conditions Options Rights that have market-based vesting conditions Fair value at grant date (weighted average) A$0.491 A$0.782 A$0.322 A$0.775 A$1.115 A$0.784 A$0.217 A$0.673 Share price at grant date (weighted average) A$0.880 A$0.927 A$0.708 A$1.170 A$1.115 A$1.022 A$1.008 A$0.931 Vesting hurdle (30-day VWAP) (weighted average) - - A$3.49 - - A$3.65 - A$3.01 Exercise price (weighted average) A$1.03 - - A$1.33 - - A$0.24 - Expected life (weighted average) (1) 3.31 years 4.42 years 3.51 years 3.99 years 3.74 years 4.28 years 5.08 years 4.57 years Risk-free interest rate (weighted average) 3.310 % — 2.965 % 0.175% - 1.317 % 1.20 % 1.266 % Expected volatility (weighted average) (2) 87 % — 78 % 100% - 100 % 100 % 100 % Expected dividend yield (3) - - - - - - - - Notes: (1) The expected life is based on the expiry date of the options or rights. (2) The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. (3) The dividend yield reflects the assumption that the current dividend payout will remain unchanged.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Jun. 30, 2023
SEGMENT INFORMATION [Abstract]
SEGMENT INFORMATION	18. SEGMENT INFORMATION IFRS 8 requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The Consolidated Entity operates in one segment, being exploration and evaluation of mineral properties in the U.S. and research and development of associated metals technologies to support an integrated titanium processing operation. (a) Reconciliation of non-current assets by geographical location 2023 2022 US$ US$ United States of America 10,048,804 3,819,215 10,048,804 3,819,215

FINANCIAL RISK MANAGEMENT OBJEC

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES	12 Months Ended
	Jun. 30, 2023
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES [Abstract]
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES	19. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (a) Overview The Group’s principal financial instruments comprise cash, receivables, other financial assets, payables, loans and borrowings and lease liabilities. The main risks arising from the Group’s financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. This note presents information about the Group’s exposure to each of the above risks, its objectives, policies and processes for measuring and managing risk, and the management of capital. The Group manages its exposure to key financial risks in accordance with the Group’s financial risk management policy. Key risks are monitored and reviewed as circumstances change and policies are revised as required. The overall objective of the Group’s financial risk management policy is to support the delivery of the Group’s financial targets whilst protecting future financial security. Given the nature and size of the business and uncertainty as to the timing and amount of cash inflows and outflows, the Group does not enter into derivative transactions to mitigate the financial risks. In addition, the Group’s policy is that no trading in financial instruments shall be undertaken for the purposes of making speculative gains. As the Group’s operations change, the Directors will review this policy periodically going forward. The Board of Directors has overall responsibility for the establishment and oversight of the risk management framework. The Board reviews and agrees policies for managing the Group’s financial risks as summarised below. (b) Credit Risk Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. This arises principally from cash and cash equivalents, receivables, and other financial assets. There are no significant concentrations of credit risk within the Group. The carrying amount of the Group’s financial assets represents the maximum credit risk exposure, as represented below: 2023 2022 Note US$ US$ Cash and cash equivalents 5 11,937,941 5,672,551 Trade and other receivables 228,395 22,540 Other financial assets – 250,000 12,166,336 5,945,091 With respect to credit risk arising from cash and cash equivalents, the Group’s exposure arises from default of the counter party, with a maximum exposure equal to the carrying amount of these instruments. Trade and other receivables comprise primarily deposits, accrued interest and GST refunds due. Where possible the Group trades only with recognised, creditworthy third parties. It is the Group’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Group’s exposure to bad debts is not significant. At June 30, 2023 none of the Group’s receivables are past due. (c) Liquidity Risk Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Board’s approach to managing liquidity is to ensure, as far as possible, that the Group will always have sufficient liquidity to meet its liabilities when due. At June 30, 2023, the Group had sufficient liquid assets to meet its financial obligations. The Group had no financial covenants during the 2023 and 2022 financial periods, as the Group’s lease liabilities and other loans and borrowings do not impose any financial covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. The contractual maturities of financial liabilities, including estimated interest payments, are provided below. There are no netting arrangements in respect of financial liabilities. ≤1 year 1-5 years ≥5 years Total contractual cash flows Carrying amount of liabilities US$ US$ US$ US$ US$ 2023 Financial liabilities Trade and other payables 1,180,984 - - 1,180,984 1,180,984 Lease liabilities 376,655 613,773 - 990,427 943,035 Other loans and borrowings 5,970 27,988 - 33,958 30,862 1,563,609 641,761 - 2,205,370 2,154,881 2022 Financial liabilities Trade and other payables 1,899,348 - - 1,899,348 1,899,348 Lease liabilities 167,619 421,142 - 588,761 506,573 Other loans and borrowings 7,811 31,242 4,556 43,609 36,457 2,074,778 452,384 4,556 2,531,718 2,442,378 (d) Interest Rate Risk The Group’s exposure to the risk of changes in market interest rates relates primarily to the cash and short-term deposits with a floating interest rate. These financial assets with variable rates expose the Group to cash flow interest rate risk. All other financial assets and liabilities are either non-interest bearing (for example, receivables and payables) or have fixed interest rates (for example, lease liabilities, sub-lease receivables, and loans and borrowings). At the reporting date, the interest rate profile of the Group’s interest-bearing financial instruments was: 2023 2022 Note US$ US$ Interest-bearing financial instruments Cash at bank and on hand 5 11,937,941 5,672,551 11,937,941 5,672,551 The Group’s cash at bank and on hand and short-term deposits had a weighted average floating interest rate at year end of 3.09% (2022: 0.31%). The Group currently does not engage in any hedging or derivative transactions to manage interest rate risk. Interest rate sensitivity A sensitivity of 0.5% (50 basis points) has been selected as this is considered reasonable given the current level of both short term and long-term interest rates. A 0.5% (50 basis points) movement in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant. Profit or loss Equity +0.5% US$ -0.5% US$ +0.5% US$ -0.5% US$ 2023 Cash and cash equivalents 59,690 (59,690 ) 59,690 (59,690 ) 2022 Cash and cash equivalents 28,363 (28,363 ) 28,363 (28,363 ) (e) Foreign Currency Risk Foreign currency risk is the risk that the fair value of future cash outflows of an exposure will fluctuate because of changes in foreign currency exchange rates. The Group’s exposure to the risk of changes in foreign exchange rate relates primarily to assets and liabilities that are denominated in currencies other than the functional currency of the group entity. The Company’s functional currency is Australian dollars. The financial statements are presented in United States dollars which is the Group’s presentation currency. The Group also has transactional currency exposures relating to transactions denominated in currencies other than the functional currency of the entity. It is the Group’s policy not to enter into any hedging or derivative transactions to manage foreign currency risk. At the reporting date, the Group’s exposure to financial instruments denominated in currencies other than the functional currency of the group entity: Assets and liabilities denominated in currencies other than the functional currency of the group entity 2023 2022 Financial assets Cash and cash equivalents 8,498,094 2,040,266 Financial liabilities Trade and other payables (171,559 ) (438,282 ) Net exposure 8,326,535 1,601,984 Foreign exchange rate sensitivity At the reporting date, had the US$ appreciated or depreciated against the $A, as illustrated in the table below, profit or loss and equity would have been affected by the amounts shown below. This analysis assumes that all other variables remain constant. Profit or loss Equity +10% US$ -10% US$ +10% US$ -10% US$ 2023 Group 832,653 (832,653 ) 832,653 (832,653 ) 2022 Group 160,198 (160,198 ) 160,198 (160,198 ) (f) Commodity Price Risk The Group is exposed to commodity price risk. These commodity prices can be volatile and are influenced by factors beyond the Group’s control. As the Group is currently engaged in the exploration and evaluation of its mineral properties in the U.S. and the research and development of its associated metals technologies, no sales of commodities are forecast for the next 12 months, and accordingly, no hedging or derivative transactions have been used to manage commodity price risk. (g) Capital Management The Board’s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Given the stage of development of the Group, the Board’s objective is to minimise debt and to raise funds as required through the issue of new shares. The Group is not subject to externally imposed capital requirements. There were no changes in the Group’s approach to capital management during the year. (h) Fair Value The fair value of financial assets and financial liabilities approximates their carrying value. The methods for estimating fair value are outlined in the relevant notes to the consolidated financial statements.

CONTINGENT ASSETS AND LIABILITI

CONTINGENT ASSETS AND LIABILITIES	12 Months Ended
	Jun. 30, 2023
CONTINGENT ASSETS AND LIABILITIES [Abstract]
CONTINGENT ASSETS AND LIABILITIES	20. CONTINGENT ASSETS AND LIABILITIES Titan Project At June 30, 2023, the Group had entered into exclusive option agreements with local landowners in Tennessee, United States, in relation to its Titan Project, which upon exercise, allows the Group to lease or, in some cases purchase, approximately 10,618 acres of surface property and the associated mineral rights from the local landowners. During the option period, our option agreements provide us with exclusive right to access, enter, occupy and use the surface property for all purposes related to exploring for and evaluating all minerals in return for making annual option payments and bonus payments during periods when we conduct drilling. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium. Blacksand At June 30, 2023, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. IperionX can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable in each of January 2023, July 2023, January 2024 and July 2024). If IperionX chooses to exercise its option, IperionX shall pay Blacksand: (1) any option payments that have not been paid at the date of exercise; and (2) an additional US$6,000,000. Subject to shareholder approval, IperionX may elect to satisfy 30% of the total purchase price through the issue of shares in IperionX. IperionX shall also commit to donate US$1,000,000 to establish an endowed chair professorship at the University of Utah in Dr. Fang’s name. If net sales from the acquired assets exceed US$300,000,000, then IperionX shall pay Blacksand a royalty equal to 0.5% of net sales in excess of US$300,000,000 for the life of the licensed patents. If IperionX chooses not to exercise its option, IperionX retains options to licence key technologies from Blacksand, including HAMR and GSD technologies that can produce low-cost and low-carbon titanium metal, for consideration comprising a license fee and a royalty.

EVENTS SUBSEQUENT TO BALANCE DA

EVENTS SUBSEQUENT TO BALANCE DATE	12 Months Ended
	Jun. 30, 2023
EVENTS SUBSEQUENT TO BALANCE DATE [Abstract]
EVENTS SUBSEQUENT TO BALANCE DATE	21. EVENTS SUBSEQUENT TO BALANCE DATE As at the date of this report there are no other matters or circumstances which have arisen since June 30, 2023 that have significantly affected or may significantly affect: • the operations, in financial years subsequent to June 30, 2023, of the Group; • the results of those operations, in financial years subsequent to June 30, 2023, of the Group; or • the state of affairs, in financial years subsequent to June 30, 2023, of the Group.

STATEMENT OF SIGNIFICANT ACCO_2

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2023
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of preparation	(a) Basis of preparation The financial report is a general purpose financial report, which has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial report has also been prepared on a historical cost basis, except for other financial assets, which have been measured at fair value. The consolidated financial statements are presented in United States dollars (US$). Going concern The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business. The Group currently has no source of material operating cash inflows and had net outflows from operating and investing activities of US$21,569,980 for fiscal 2023 (2022: US$15,200,544). At June 30, 2023, the Group has cash and cash equivalents of US$11,937,941 (2022: US$5,672,551). The ongoing operation of the Group is dependent upon raising further additional funding from shareholders or other parties. In light of increasing expenditures to be incurred in executing on the Group’s current strategic plans to commercialize the Group’s titanium metal technologies and develop economically recoverable mineral deposits from the Group’s exploration properties, the Group is dependent on obtaining financing through equity financing, debt financing or other means. In the longer term, if the Group’s exploration, appraisal, and pilot activities are ultimately successful, additional funds will be required to develop the Group’s titanium metal technologies and exploration properties and commence commercial production. The ability to arrange such funding in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Group. There is no assurance that the Group will be successful in its efforts to raise additional funding on terms satisfactory to the Group. If the Group does not obtain additional funding, it may not be able to continue its operations as a going concern and therefore may not be able to realize its assets and extinguish its liabilities in the ordinary course of operations and at the amounts stated in the financial statements. Alternatively, the Group may be required to delay, reduce the scope of, or eliminate its current or future exploration, appraisal, and pilot activities or relinquish rights to certain of its interests. The Directors are confident that they will be able to raise additional funds as required to meet its obligations as and when they fall due and are of the opinion that the use of the going concern basis remains appropriate. However as a result of these matters, there is a material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (“PCAOB”) standards) on the Group’s ability to continue as a going concern, and therefore the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. Comparative figures When applicable, certain comparative figures have been adjusted to conform to the current year’s presentation. These changes had no impact on the Group’s net loss or financial position for the year ended June 30, 2022 or period from July 20, 2020 to June 30, 2021. In the comparative figures for the period from July 20, 2020 to June 30, 2021, the Group has revised the loss per share in the consolidated statement of profit or loss to reflect the impact of the reverse acquisition in determining the weighted average number of ordinary shares. The revision reduces the basic and diluted loss per share from US$0.22 to US$0.19 per share. This change had no impact on the Group’s net loss or financial position for the period ended June 30, 2021. Whilst the Group considers the change to be immaterial, the Group has revised the previously reported loss per share presented for comparative purposes.
New standards, interpretations and amendments	(b) New standards, interpretations and amendments In the current year, the Group has adopted all of the new and revised Accounting Standards and Interpretations effective from July 1, 2022 that are mandatory. The adoption of the aforementioned standards has no impact on the financial statements of the Company as at June 30, 2023. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
Issued standards and interpretations not early adopted	(c) Issued standards and interpretations not early adopted International Financial Reporting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the year ended June 30, 2023. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group’s financial statements: Standard/Interpretation Application Date of Standard Application Date for the Group Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12) 1 January 2023 1 July 2023 Definition of Accounting Estimates (Amendments to IAS 8) 1 January 2023 1 July 2023 Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) 1 January 2023 1 July 2023 Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) 1 January 2024 1 July 2024 Lease Liability in a Sale and Leaseback (Amendments to IFRS 16) 1 January 2024 1 July 2024 Non-current Liabilities with Covenants (Amendments to IAS 1) 1 January 2024 1 July 2024
Principles of Consolidation	(d) Principles of Consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company. Control is achieved when the Company has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power. Subsidiaries are all those entities (including special purpose entities) over which the Company has the power to govern the financial and operating policies, so as to obtain benefits from its activities, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity. The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. Intercompany transactions and balances, income and expenses and profits and losses between Group companies, are eliminated. Investments in subsidiaries are accounted for at cost in the Statement of Financial Position of the Company.
Foreign Currencies	(e) Foreign Currencies (i) Functional and presentation currency The functional currency of each of the Group’s entities is measured using the currency of the primary economic environment in which that entity operates. The Company’s functional currency is Australian dollars. The Group’s financial statements are presented in United States dollars which is the Group’s presentation currency. United States dollars has been chosen as the Group’s presentation currency to better reflect the Groupʼs business activities in the United States and to enhance comparability with its industry peer group, the majority of which report in United States dollars. (ii) Transactions and balances Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined. Exchange differences arising on the translation of monetary items are recognised in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge. Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the income statement. (iii) Group companies The financial results and position of operations whose functional currency is different from the group’s presentation currency are translated as follows: • assets and liabilities are translated at year-end exchange rates prevailing at that reporting date; • income and expenses are translated at average exchange rates for the year; and • retained earnings are translated at the exchange rates prevailing at the date of the transaction. Exchange differences arising on translation into the presentation currency are transferred directly to the group’s foreign currency translation reserve in equity. These differences are recognised in profit or loss in the year in which the operation is disposed.
Cash and Cash Equivalents	(f) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of 3 months or less.
Trade and Other Receivables	(g) Trade and Other Receivables Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less allowance for expected credit losses, applying the simplified approach. If collection of the amounts is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. Trade receivables are generally due for settlement within 30 days and therefore are all classified as current. As the majority of receivables are short term in nature, their carrying amount is assumed to be the same as their fair value.
Prepayments	(h) Prepayments Prepayments represent payments in advance of receipt of goods or services. The Group recognises a prepayment as an asset within other current and non-current assets when payment for goods or services has been made in advance of the Group obtaining a right to access those goods or services. Ther Group’s prepayments comprise of certain option payments made to Blacksand Technology, LLC as part of the Group’s exclusive option to purchase the assets of Blacksand. Upon exercise of the option, the prepaid amounts will transfer to the capital cost of the asset. These prepayments are assessed for indicators of impairment each year. If future economic benefits are no longer expected to occur, for example, if purchase of assets of Blacksand is no longer probable, and economic benefits cannot be derived from the prepayment in any other way, such as the absence of the ability to sell the option to another party or obtain a refund, the prepayment will be derecognised.
Property, Plant and Equipment	(i) Property, Plant and Equipment All classes of property, plant and equipment are measured at cost. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, except for land which is not depreciated. Currently the Group only has plant and equipment which is depreciated over a period of 5 years.
Exploration and Development Expenditure	(j) Exploration and Development Expenditure Expenditure on exploration and evaluation is accounted for in accordance with the ‘area of interest’ method and with IFRS 6 Exploration for and Evaluation of Mineral Resources. Exploration and evaluation expenditure encompasses expenditures incurred by the Group in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource are demonstrable. For each area of interest, expenditure incurred in the acquisition of rights to explore is capitalised and recognised as an exploration and evaluation asset. This includes option payments made to landowners under the Group’s option agreements with local landowners which are considered part of the acquisition costs. Exploration and evaluation assets are measured at cost at recognition and are recorded as an asset if: (i) the rights to tenure of the area of interest are current; and (ii) at least one of the following conditions is also met: • the exploration and evaluation expenditures are expected to be recouped through successful development and exploitation of the area of interest, or alternatively, by its sale; and • exploration and evaluation activities in the area of interest have not at the reporting date reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area of interest are continuing. All other exploration and evaluation expenditures are expensed as incurred. Once the technical feasibility and commercial viability of a program or project has been demonstrated with a bankable feasibility study, the carrying amount of the exploration and evaluation expenditure in respect of the area of interest is reclassified as a “mine development property”. Where a decision is made to proceed with development, accumulated expenditure is tested for impairment and transferred to development properties, and then amortised over the life of the reserves associated with the area of interest once mining operations have commenced. Recoverability of the carrying amount of the exploration and evaluation assets is dependent on successful development and commercial exploitation, or alternatively, sale of the respective areas of interest. Impairment Capitalised exploration costs are reviewed each reporting date to establish whether an indication of impairment exists. If any such indication exists, the recoverable amount of the capitalised exploration costs is estimated to determine the extent of the impairment loss (if any). Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset.
Research and Development Expenditure	(k) Research and Development Expenditure Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Group can demonstrate: (a) the technical feasibility of completing the intangible asset so that the asset will be available for use or sale; (b) its intention to complete and its ability and intention to use or sell the asset; (c) how the asset will generate future economic benefits; (d) the availability of resources to complete the asset; and (e) the ability to measure reliably the expenditure during development. Development costs that do not meet these criteria are expensed as incurred. Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete, and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.
Trade and other payables	(l) Trade and other payables These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method. The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature.
Provisions	(m) Provisions Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.
Interest income	(n) Interest income Interest income is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.
Income Tax	(o) Income Tax The income tax expense for the year is the tax payable on the current year’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses. Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised. Unrecognised deferred income tax assets are reassessed at each balance date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority.
Employee Entitlements	(p) Employee Entitlements Provision is made for the Group’s liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled wholly within 12 months have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.
Earnings per Share	(q) Earnings per Share Basic earnings per share (“EPS”) is calculated by dividing the net profit attributable to members of the Company for the reporting period, after excluding any costs of servicing equity, by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue. Diluted EPS is calculated by dividing the basic EPS earnings, adjusted by the after tax effect of financing costs associated with dilutive potential Ordinary Shares and the effect on revenues and expenses of conversion to Ordinary Shares associated with dilutive potential Ordinary Shares, by the weighted average number of Ordinary Shares and dilutive Ordinary Shares adjusted for any bonus issue.
Use and Revision of Accounting Estimates, Judgements and Assumptions	(r) Use and Revision of Accounting Estimates, Judgements and Assumptions The preparation of the financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year, or in the year of the revision and future years if the revision affects both current and future years. In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are described in the following note: • Functional currency (Note 1(e)); • Impairment of exploration and evaluation assets (Note 7); and • Share-based payments (Note 17).
Operating Segments	(s) Operating Segments An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors. Operating segments have been identified based on the information provided to the chief operating decision makers, being the board of directors. The group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects: • Nature of the products and services, • Nature of the production processes, • Type or class of customer for the products and services, • Methods used to distribute the products or provide the services, and if applicable, • Nature of the regulatory environment. Operating segments that meet the quantitative criteria as prescribed by IFRS 8 Operating Segments Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”. Currently, the Group has only one operating segment.
Impairment of Non-Financial Assets	(t) Impairment of Non-Financial Assets The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Group makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs of disposal and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount. In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. After such a reversal the depreciation charge is adjusted in future years to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
Fair Value Estimation	(u) Fair Value Estimation The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes. The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities classified as fair value through other comprehensive income) is based on quoted market prices at the reporting date. The quoted market price used for financial assets held by the Group is the current bid price; the appropriate quoted market price for financial liabilities is the current ask price. The fair value of financial instruments that are not traded in an active market (for example, over the counter derivatives) is determined using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each balance date. Quoted market prices or dealer quotes for similar instruments are used for long-term debt instruments held. Other techniques, such as discounted cash flows, are used to determine fair value for the remaining financial instruments. The fair value of interest-rate swaps is calculated as the present value of the estimated future cash flows. The fair value of forward exchange contracts is determined using forward exchange market rates at the reporting date. The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.
Issued and Unissued Capital	(v) Issued and Unissued Capital Ordinary Shares and Performance Shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Dividends	(w) Dividends Provision is made for the amount of any dividend declared on or before the end of the year but not distributed at balance date.
Share-Based Payments	(x) Share-Based Payments Equity-settled share-based payments are provided to officers, employees, consultants and other advisors. These share-based payments are measured at the fair value of the equity instrument at the grant date. The fair value of options is estimated using the Black Scholes option valuation model. The fair value of performance rights that have market-based vesting conditions is estimated using a trinomial valuation model. The fair value of restricted stock units and performance rights that do not have market-based vesting conditions are estimated based on the underlying share price. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of equity instruments that will eventually vest. At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss over the remaining vesting period, with a corresponding adjustment to the share-based payments reserve. Equity-settled share-based payments may also be provided as consideration for the acquisition of assets. Where ordinary shares are issued, the transaction is recorded at fair value based on the quoted price of the ordinary shares at the date of issue. The acquisition is then recorded as an asset or expensed in accordance with accounting standards.
Leases	(y) Leases The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognises right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. Lease liabilities At the commencement date of the lease, the Group recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating the lease, if the lease term reflects the Group exercising the option to terminate. In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. Short-term leases and leases of low-value assets The Group applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e. those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

STATEMENT OF SIGNIFICANT ACCO_3

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2023
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Australian Financial Reporting Standards and Interpretations Not Yet Applied	International Financial Reporting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the year ended June 30, 2023. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group’s financial statements: Standard/Interpretation Application Date of Standard Application Date for the Group Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12) 1 January 2023 1 July 2023 Definition of Accounting Estimates (Amendments to IAS 8) 1 January 2023 1 July 2023 Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) 1 January 2023 1 July 2023 Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) 1 January 2024 1 July 2024 Lease Liability in a Sale and Leaseback (Amendments to IFRS 16) 1 January 2024 1 July 2024 Non-current Liabilities with Covenants (Amendments to IAS 1) 1 January 2024 1 July 2024

INCOME AND EXPENSES (Tables)

INCOME AND EXPENSES (Tables)	12 Months Ended
	Jun. 30, 2023
INCOME AND EXPENSES [Abstract]
Income and Expenses	2023 2022 July 20, 2020 to June 30, 2021 Note US$ US$ US$ Finance income Interest income 139,697 24,042 5,075 Net foreign exchange gain 354,772 377,003 - 494,469 401,045 5,075 Finance costs Interest expense (88,138 ) (45,541 ) (3,097 ) Other finance costs - (6,734 ) (4,395 ) (88,138 ) (52,275 ) (7,492 ) Other income and expenses Other income 60,470 - - Loss on derecognition of financial asset (250,000 ) - - Cost of listing on reverse acquisition - - (5,141,126 ) (189,530 ) - (5,141,126 ) Depreciation and amortisation Amortisation of right-of-use assets 8 (249,387 ) (119,706 ) (8,364 ) Depreciation of property, plant and equipment 8 (177,147 ) (33,728 ) (960 ) (426,534 ) (153,434 ) (9,324 ) Employee benefits expense Wages and salaries (4,714,673 ) (2,739,427 ) (509,474 ) Employee benefits (808,717 ) (376,974 ) (44,325 ) Post-employment benefits (134,074 ) (67,496 ) (8,929 ) Share-based payment expenses (2,589,413 ) (8,340,328 ) (4,084,764 ) (8,246,877 ) (11,524,225 ) (4,647,492 )

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Jun. 30, 2023
INCOME TAX [Abstract]
Income Tax	2023 2022 July 20, 2020 to June 30, 2021 Note US$ US$ US$ Recognised in profit or loss Current income tax: Current income tax benefit in respect of the current year - - - Deferred income tax: Origination and reversal of temporary differences - - - Income tax expense reported in profit or loss - - - Reconciliation between tax expense and accounting loss before income tax Accounting loss before income tax (17,444,754 ) (21,521,237 ) (13,230,837 ) At the Australian income tax rate of 30 (5,233,426 ) (6,456,371 ) (3,969,251 ) Effect of lower income tax rate in the United States 488,952 433,351 124,391 Expenditure not allowable for income tax purposes 870,584 2,502,099 2,942,127 Exchange differences 5,329 30,731 (5,365 ) Adjustments in respect of deferred tax of previous years (182,314 ) 174,258 - Effect of deferred tax assets not brought to account 4,050,875 3,315,932 908,098 Income tax expense reported in profit or loss - - - Deferred tax assets and liabilities Deferred tax liabilities: Right-of-use assets 305,000 121,755 142,128 Deferred tax assets used to offset deferred tax liabilities (305,000 ) (121,755 ) (142,128 ) - - - Deferred tax assets: Accrued expenditures 139,113 22,500 53,997 Provisions 21,956 12,125 2,893 Lease liabilities 246,832 132,393 142,695 Capital allowances 3,241,541 2,535,077 - Tax losses available to offset against future taxable income 5,361,043 2,053,718 1,260,669 Deferred tax assets used to offset deferred tax liabilities (305,000 ) (121,755 ) (142,128 ) Deferred tax assets acquired on reverse acquisition not brought to account (1) - - (410,028 ) Other deferred tax assets not brought to account (1) (8,705,485 ) (4,634,058 ) (908,098 ) - - - Notes: (1) The benefit of deferred tax assets not brought to account will only be subsequently recognised if: (a) future assessable income is derived of a nature and of an amount sufficient to enable the benefit to be realised; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realising the benefit.

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Jun. 30, 2023
CASH AND CASH EQUIVALENTS [Abstract]
Cash and Cash equivalents and Reconciliation of Loss Before Income Tax to Net Cash Flows from Operations	2023 2022 July 20, 2020 to June 30, 2021 US$ US$ US$ Cash at bank and on hand 11,937,941 5,672,551 1,697,904 11,937,941 5,672,551 1,697,904 Reconciliation of loss before income tax to net cash flows from operations Loss for the year (17,444,754 ) (21,521,237 ) (13,230,837 ) Adjustment for non-cash income and expense items Share-based payments expense 2,589,413 8,340,328 4,084,764 Amortisation of right-of-use assets 249,387 119,706 8,364 Depreciation of property, plant and equipment 177,147 33,728 960 Net foreign exchange loss/(gain) (354,772 ) (377,003 ) - Loss on derecognition of financial asset 250,000 - - Lease modifications - (2,112 ) - Cost of listing on reverse acquisition - - 5,141,126 Changes in assets and liabilities Increase in receivables and prepayments (650,067 ) (98,797 ) (34,405 ) (Decrease)/increase in payables and provisions (680,748 ) 1,371,310 472,003 Net cash outflow from operating activities (15,864,394 ) (12,134,077 ) (3,558,025 )

PREPAYMENTS (Tables)

PREPAYMENTS (Tables)	12 Months Ended
	Jun. 30, 2023
PREPAYMENTS [Abstract]
PREPAYMENTS	2023 2022 US$ US$ Current Other prepayments 588,395 144,183 Total current prepayments 588,395 144,183 Non-current Blacksand option prepayments (1) 3,000,000 - Total non-current prepayments 3,000,000 - Total prepayments 3,588,395 144,183 Notes: (1) At June 30, 2023, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. The Group can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable by January 2023, July 2023, January 2024 and July 2024). These prepayments represent the first two option payments to Blacksand, paid in December 2022 and June 2023. Refer Note 21 for further details.

EXPLORATION AND EVALUATION AS_2

EXPLORATION AND EVALUATION ASSETS (Tables)	12 Months Ended
	Jun. 30, 2023
EXPLORATION AND EVALUATION ASSETS [Abstract]
Exploration and Evaluation Assets	Titan Project (1) US$ 2023 Carrying amount at July 1, 2022 2,431,229 Additions 627,792 Carrying amount at June 30, 2023 (2) 3,059,021 2022 Carrying amount at July 1, 2021 504,750 Additions 1,926,479 Carrying amount at June 30, 2022 (2) 2,431,229 Notes: (1) At June 30, 2023, the Titan Project comprised of approximately 11,071 acres of surface and associated mineral rights in Tennessee prospective for heavy mineral sands, including titanium, rare earth minerals, high grade silica sand, and zircon, of which approximately 453 acres are owned and approximately 10,618 acres are subject to exclusive option agreements. These exclusive option agreements, upon exercise, allow the Group to lease, or in some cases purchase, the surface property and associated mineral rights. (2) The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2023
PROPERTY, PLANT AND EQUIPMENT [Abstract]
Property, Plant and Equipment	Plant and Right-of-use assets Total US$ US$ US$ 2023 Carrying amount at July 1, 2022 922,118 465,868 1,387,986 Additions 2,077,794 950,537 3,028,331 Depreciation and amortization (177,147 ) (249,387 ) (426,534 ) Carrying amount at June 30, 2023 2,822,765 1,167,018 3,989,783 - at cost 3,034,599 1,543,876 4,578,475 - accumulated depreciation (211,834 ) (376,858 ) (588,692 ) 2022 Carrying amount at July 1, 2021 65,858 473,761 539,619 Additions 889,988 140,188 1,030,176 Modifications - (28,375 ) (28,375 ) Depreciation and amortization (33,728 ) (119,706 ) (153,434 ) Carrying amount at June 30, 2022 922,118 465,868 1,387,986 - at cost 956,805 593,339 1,550,144 - accumulated depreciation (34,687 ) (127,471 ) (162,158 )

TRADE AND OTHER PAYABLES (Table

TRADE AND OTHER PAYABLES (Tables)	12 Months Ended
	Jun. 30, 2023
TRADE AND OTHER PAYABLES [Abstract]
Trade and Other Payables	2023 2022 US$ US$ Current Trade payables 711,011 1,677,757 Accruals 455,241 196,450 Payroll liabilities 14,732 25,141 Total trade and other payables 1,180,984 1,899,348

LOANS AND BORROWINGS (Tables)

LOANS AND BORROWINGS (Tables)	12 Months Ended
	Jun. 30, 2023
LOANS AND BORROWINGS [Abstract]
Loans and Borrowings	2023 2022 US$ US$ Current Lease liabilities 376,655 128,653 Other loans and borrowings 5,971 5,594 Total current loans and borrowings 382,626 134,247 Non-current Lease liabilities 567,796 377,920 Other loans and borrowings 24,892 30,863 Total non-current loans and borrowings 592,688 408,783 Total loans and borrowings 975,314 543,030
Reconciliation of Loans and Borrowings	(a) Reconciliation Balance at Additions Repayments Balance at June 30, 2023 US$ US$ US$ US$ Lease liabilities 506,573 950,538 (512,660 ) 944,451 Other loans and borrowings 36,457 - (5,594 ) 30,863 Total loans and borrowings 543,030 950,538 (518,254 ) 975,314

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2023
LEASES [Abstract]
Amounts Recognised in Profit or Loss	The following are the amounts recognised in profit or loss in respect of leases: 2023 2022 Note US$ US$ Amortisation of right-of-use assets 8 (249,387 ) (119,706 ) Interest expense on lease liabilities (78,040 ) (44,512 ) Net amount recognised in profit or loss (327,427 ) (164,218 )

CONTRIBUTED EQUITY (Tables)

CONTRIBUTED EQUITY (Tables)	12 Months Ended
	Jun. 30, 2023
CONTRIBUTED EQUITY [Abstract]
Issued Capital	2023 2022 Note US$ US$ Issued capital 193,493,973 140,288,491 12(a) 58,764,248 29,782,268
Movements in Issued Capital	(a) Movements in issued capital Number of Ordinary Shares Number of Performance Shares Number of Performance Shares US$ 2023 Opening balance at July 1, 2022 140,288,491 19,800,000 19,800,000 29,782,268 Issue of shares – share placements 50,000,000 - - 29,637,300 Issue of shares – exercise of options 2,102,363 - - 477,156 Issue of shares – conversion of RSUs 200,001 - - 167,487 Issue of shares – conversion of performance rights 215,495 - - 216,007 Issue of shares to consultant 687,623 - - 350,000 Share issue costs - - - (1,865,970 ) Closing balance at June 30, 2023 193,493,973 19,800,000 19,800,000 58,764,248 2022 Opening balance at July 1, 2021 105,105,787 19,800,000 19,800,000 10,255,369 Issue of shares – share placements 20,000,000 - - 17,604,000 Issue of shares – exercise of options 15,182,704 - - 2,353,704 Share issue costs - - - (430,805 ) Closing balance at June 30, 2022 140,288,491 19,800,000 19,800,000 29,782,268

RESERVES (Tables)

RESERVES (Tables)	12 Months Ended
	Jun. 30, 2023
RESERVES [Abstract]
Reserves	2023 2022 Note US$ US$ Share-based payments reserve 13(b ) 15,004,052 12,985,856 Foreign currency translation reserve 13(f ) (1,008,244 ) (596,331 ) 13,995,808 12,389,525
Movements in Share-based Payments Reserve	(b) Movements in share-based payments reserve during the year Number of Listed Number of Unlisted Options Number of Performance Rights No. of Restricted Stock Units US$ 2023 Opening balance at July 1, 2022 - 23,824,000 27,620,000 600,000 12,985,856 Grant of employee incentive securities - 424,372 1,535,000 424,372 - Grant of options to financial advisor - 1,000,000 - - 354,788 Exercise of options - (2,237,000 ) - - (192,511 ) Conversion of RSUs - - (329,000 ) - (167,487 ) Conversion of performance rights - - - (200,001 ) (216,007 ) Issue of shares to a consultant - - - - (350,000 ) Lapse of employee incentive securities - - (80,000 ) - - Share-based payment expense - - - - 2,589,413 Closing balance at June 30, 2023 - 23,011,372 28,746,000 824,371 15,004,052 2022 Opening balance at July 1,2021 12,624,214 25,800,000 16,325,000 - 4,738,007 Grant of employee incentive securities - 600,000 11,295,000 600,000 - Exercise of options (12,606,704 ) (2,576,000 ) - - (92,479 ) Expiry of options (17,510 ) - - - - Share-based payment expense - - - - 8,340,328 Closing balance at June 30, 2022 - 23,824,000 27,620,000 600,000 12,985,856 Notes: (1) For details on the valuation of Unlisted Options, Performanc e Rights and Restricted Stock Units,
Movements in Foreign Currency Translation Reserve	(f) Movements in foreign currency translation reserve during the year 2023 2022 US$ US$ Balance at start of year (596,331 ) (2,419 ) Exchange differences arising on translation into presentation currency (411,913 ) (593,912 ) Balance at June 30 (1,008,244 ) (596,331 )

ACCUMULATED LOSSES (Tables)

ACCUMULATED LOSSES (Tables)	12 Months Ended
	Jun. 30, 2023
ACCUMULATED LOSSES [Abstract]
Accumulated Losses	2023 2022 US$ US$ Balance at start of year (34,752,074 ) (13,230,837 ) Net loss for the year (17,444,754 ) (21,521,237 ) Balance at June 30 (52,196,828 ) (34,752,074 )

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Jun. 30, 2023
LOSS PER SHARE [Abstract]
Basic and Diluted Loss per Share	2023 2022 US$ July 20, 2020 to June 30, 2021 Basic loss per share (1) (0.11 ) (0.16 ) (0.19 ) Diluted loss per share (1) (0.11 ) (0.16 ) (0.19 ) Notes: (1) Basic and diluted loss per share for the comparative period from July 20, 2020 to June 30, 2021 have been revised. Refer to Note 1(a) for further information
Income and Share Data Used in Calculations of Basic Earnings per Share	The following reflects the income and share data used in the calculations of basic earnings per share: 2023 2022 US$ July 20, 2020 to June 30, 2021 Net loss (17,444,754 ) (21,521,237 ) (13,230,837 ) Net loss used in calculating basic and dilutive earnings per share (17,444,754 ) (21,521,237 ) (13,230,837 ) Number of Ordinary Shares 2023 Number of Ordinary Shares 2022 Number of Ordinary Shares 2021 Weighted average number of Ordinary Shares used in calculating basic and dilutive earnings per share 168,029,357 134,609,413 68,798,762

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	12 Months Ended
	Jun. 30, 2023
RELATED PARTIES [Abstract]
Subsidiaries	(a) Subsidiaries Country of Equity Interest 2023 2022 2021 % Hyperion Metals (Australia) Pty Ltd Australia 100 100 100 IperionX Critical Minerals LLC United States 100 100 100 IperionX Technology LLC United States 100 100 100 IperionX Inc. United States 100 100 - Calatos Pty Ltd LLC United States 100 100 100
Aggregate Compensation Made to Key Management Personnel	The aggregate compensation made to Key Management Personnel of the Group is set out below: 2023 2022 July 20, 2020 to June 30, 2021 Short-term employee benefits 2,109,813 1,503,275 275,246 Post-employment benefits 47,502 25,114 6,079 Share-based payments 1,650,382 7,146,121 3,681,159 Total compensation 3,807,697 8,674,510 3,962,484

SHARE-BASED PAYMENTS (Tables)

SHARE-BASED PAYMENTS (Tables)	12 Months Ended
	Jun. 30, 2023
SHARE-BASED PAYMENTS [Abstract]
Equity Settled Share Based Payments	During fiscal 2023, fiscal 2022, and fiscal 2021 the following equity-settled share-based payments have been recognised: 2023 2022 July 20, 2020 to June 30, 2021 Expense arising from staff remuneration arrangements (2,589,413 ) (8,340,328 ) (4,084,764 ) Expense arising from cost of listing on reverse acquisition - — (5,141,126 ) Total expense arising from equity-settled share-based payment transactions (2,589,413 ) (8,340,328 ) (9,225,890 )
Number and Weighted Average Exercise Prices of Options, Rights, and RSUs Granted	The following table illustrates the number and weighted average exercise prices (“WAEP”) of Options, Rights, and RSUs granted as share-based payments during fiscal 2023, fiscal 2022, and fiscal 2021 (excluding Shares): 2023 2023 2022 2022 2021 2021 Outstanding at beginning of year 52,044,000 A$0.12 54,749,214 A$0.19 - - Options granted during the year 1,424,372 A$1.03 600,000 A$1.33 9,150,000 A$0.31 Rights granted during the year 1,535,000 - 11,295,000 - 16,325,000 - RSUs granted during the year 424,372 - 600,000 - - - Listed Options exercised during the year - - (12,606,704 ) (A$0.20 ) (3,069,120 ) (A$0.20 ) Options exercised during the year (2,237,000 ) (A$0.26 ) (2,576,000 ) (A$0.22 ) (1,350,000 ) (A$0.24 ) Rights converted during the year (329,000 ) - - - (2,000,000 ) - RSUs converted during the year (200,001 ) - - - - - Listed Options expired during the year - - (17,510 ) (A$0.20 ) - - Rights lapsed during the year (80,000 ) - - - - - Recognition of legal acquirer Listed Options - - - - 15,693,334 A$0.20 Recognition of legal acquirer Options - - - - 5,000,000 A$0.20 Recognition of legal acquirer Rights - - - - 2,000,000 - Options granted to vendors of legal acquiree - - - - 13,000,000 A$0.20 Outstanding at end of year 52,581,743 (A$0.14 ) 52,044,000 A$0.12 54,749,214 A$0.19
Options, Rights and RSUs Granted as Share-Based Payments	The following Options, Rights and RSUs were granted as share-based payments during fiscal 2023, fiscal 2022, and fiscal 2021: 2023 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Options 1,000,000 14-Sep-22 14-Sep-25 A$1.10 - $ 0.519 Series 2 Options 424,372 25-Nov-22 05-Dec-26 A$0.87 - $ 0.424 Series 3 RSUs 424,372 25-Nov-22 05-Dec-26 - - $ 0.740 Series 4 Rights 400,000 8-Aug-22 23-Apr-26 - A$3.00 $ 0.354 Series 5 Rights 400,000 8-Aug-22 23-Apr-26 - A$4.00 $ 0.293 Series 6 Rights 200,000 8-Aug-22 23-Apr-26 - - $ 0.675 Series 7 Rights 10,000 6-Sep-22 23-Apr-26 - A$2.00 $ 0.617 Series 8 Rights 15,000 6-Sep-22 23-Apr-26 - A$3.00 $ 0.496 Series 9 Rights 35,000 6-Sep-22 23-Apr-26 - A$4.00 $ 0.428 Series 10 Rights 10,000 6-Jun-22 23-Apr-26 - A$2.00 $ 0.556 Series 11 Rights 15,000 6-Jun-22 23-Apr-26 - A$3.00 $ 0.460 Series 12 Rights 20,000 6-Jun-22 23-Apr-26 - A$4.00 $ 0.390 Series 13 Rights 10,000 8-Jun-22 31-Dec-24 - - $ 0.780 Series 14 Rights 10,000 8-Jun-22 31-Dec-25 - - $ 0.780 Series 15 Rights 10,000 8-Jun-22 31-Dec-26 - - $ 0.780 Series 16 Shares 687,623 20-Dec-22 - - - $ 0.775 Series 17 Rights 400,000 1-Feb-23 31-Jan-27 - - $ 0.880 Series 18 Rights 25,000 16-Mar-23 23-Apr-26 - A$3.00 $ 0.286 Series 19 Rights 25,000 16-Mar-23 23-Apr-26 - A$4.00 $ 0.219 Series 20 Rights 175,000 1-Apr-23 23-Apr-26 - A$3.00 $ 0.321 Series 21 Rights 175,000 1-Apr-23 23-Apr-26 - A$4.00 $ 0.247 2022 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Rights 200,000 19-Jul-21 22-Dec-24 - - $ 0.930 Series 2 Rights 200,000 19-Jul-21 22-Dec-25 - - $ 0.930 Series 3 Rights 200,000 19-Jul-21 22-Dec-26 - - $ 0.930 Series 4 Rights 25,000 19-Jul-21 23-Apr-26 - $ 4.00 $ 0.710 Series 5 Rights 25,000 19-Jul-21 23-Apr-24 - $ 2.00 $ 0.699 Series 6 Rights 25,000 19-Jul-21 23-Apr-24 - $ 3.00 $ 0.591 Series 7 Rights 1,000,000 01-Sep-21 23-Apr-26 - $ 3.00 $ 1.195 Series 8 Rights 1,000,000 01-Sep-21 23-Apr-26 - $ 4.00 $ 1.131 Series 9 RSUs 600,000 13-Sep-21 09-Sep-25 - - $ 1.170 Series 10 Options 600,000 13-Sep-21 09-Sep-25 $ 1.33 - $ 0.775 Series 11 Rights 4,000 11-Oct-21 22-Dec-24 - - $ 1.100 Series 12 Rights 6,000 11-Oct-21 22-Dec-25 - - $ 1.100 Series 13 Rights 10,000 11-Oct-21 22-Dec-26 - - $ 1.100 Series 14 Rights 40,000 12-Oct-21 22-Dec-24 - - $ 1.070 Series 15 Rights 40,000 12-Oct-21 22-Dec-25 - - $ 1.070 2022 (Continued) Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 16 Rights 40,000 12-Oct-21 22-Dec-26 - - $ 1.070 Series 17 Rights 225,000 14-Oct-21 23-Apr-26 - $ 4.00 $ 0.801 Series 18 Rights 25,000 14-Oct-21 23-Apr-24 - $ 2.00 $ 0.790 Series 19 Rights 125,000 14-Oct-21 23-Apr-24 - $ 3.00 $ 0.663 Series 20 Rights 15,000 08-Nov-21 22-Dec-24 - - $ 0.955 Series 21 Rights 15,000 08-Nov-21 22-Dec-25 - - $ 0.955 Series 22 Rights 15,000 08-Nov-21 22-Dec-26 - - $ 0.955 Series 23 Rights 30,000 15-Nov-21 31-Dec-24 - - $ 0.990 Series 24 Rights 30,000 15-Nov-21 31-Dec-25 - - $ 0.990 Series 25 Rights 30,000 15-Nov-21 31-Dec-26 - - $ 0.990 Series 26 Rights 3,500,000 25-Nov-21 23-Apr-26 - $ 4.00 $ 0.644 Series 27 Rights 250,000 06-Dec-21 23-Apr-26 - $ 2.00 $ 0.703 Series 28 Rights 250,000 06-Dec-21 23-Apr-26 - $ 3.00 $ 0.642 Series 29 Rights 500,000 06-Dec-21 23-Apr-26 - $ 4.00 $ 0.594 Series 30 Rights 50,000 15-Dec-21 22-Dec-26 - - $ 0.752 Series 31 Rights 314,998 15-Dec-21 23-Apr-26 - $ 2.00 $ 0.728 Series 32 Rights 100,000 15-Dec-21 22-Dec-26 - - $ 0.700 Series 33 Rights 315,001 15-Dec-21 23-Apr-26 - $ 3.00 $ 0.665 Series 34 Rights 150,000 15-Dec-21 22-Dec-26 - - $ 0.658 Series 35 Rights 325,001 15-Dec-21 23-Apr-26 - $ 4.00 $ 0.616 Series 36 Rights 30,000 01-Jan-22 31-Dec-24 - - $ 0.910 Series 37 Rights 30,000 01-Jan-22 31-Dec-25 - - $ 0.910 Series 38 Rights 30,000 01-Jan-22 31-Dec-26 - - $ 0.910 Series 39 Rights 50,000 01-Jan-22 22-Dec-25 - $ 4.00 $ 0.634 Series 40 Rights 25,000 31-Jan-22 22-Dec-26 - $ 4.00 $ 0.695 Series 41 Rights 25,000 31-Jan-22 22-Dec-24 - $ 2.00 $ 0.684 Series 42 Rights 25,000 31-Jan-22 22-Dec-25 - $ 3.00 $ 0.677 Series 43 Rights 1,000,000 29-Mar-22 06-Apr-25 - - $ 1.235 Series 44 Rights 1,000,000 29-Mar-22 06-Apr-25 - $ 4.00 $ 0.840 2021 Security Number Grant Date Expiry Exercise Vesting Hurdle Fair Series 1 Options 7,000,000 01-Dec-20 31-Dec-23 $ 0.25 - $ 0.163 Series 2 Options 5,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 3 Options 4,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 4 Options 4,000,000 01-Dec-20 01-Dec-25 $ 0.20 - $ 0.201 Series 5 Options 5,000,000 01-Dec-20 31-Dec-23 $ 0.20 - $ 0.174 Series 6 Rights 150,000 03-Mar-21 01-Mar-26 - $ 2.00 $ 0.694 Series 7 Rights 150,000 03-Mar-21 01-Mar-26 - $ 3.00 $ 0.643 Series 8 Rights 150,000 03-Mar-21 01-Mar-26 - $ 4.00 $ 0.602 Series 9 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 2.00 $ 0.745 Series 10 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 3.00 $ 0.693 Series 11 Rights 2,000,000 14-Apr-21 23-Apr-26 - $ 4.00 $ 0.651 Series 12 Options 875,000 14-Apr-21 31-Dec-23 $ 0.45 - $ 0.605 Series 13 Options 875,000 14-Apr-21 31-Dec-23 $ 0.55 - $ 0.575 Series 14 Rights 125,000 15-Apr-21 23-Apr-24 - $ 2.00 $ 0.599 Series 15 Rights 125,000 15-Apr-21 23-Apr-24 - $ 3.00 $ 0.510 Series 16 Rights 125,000 15-Apr-21 23-Apr-24 - $ 4.00 $ 0.445 Series 17 Rights 2,875,000 15-Apr-21 23-Apr-26 - $ 2.00 $ 0.705 Series 18 Rights 2,875,000 15-Apr-21 23-Apr-26 - $ 3.00 $ 0.654 Series 19 Rights 2,975,000 15-Apr-21 23-Apr-26 - $ 4.00 $ 0.613 Series 20 Options 200,000 15-Apr-21 31-Dec-23 $ 0.45 - $ 0.570 Series 21 Options 200,000 15-Apr-21 31-Dec-23 $ 0.55 - $ 0.540 Series 22 Rights 258,333 22-Jun-21 23-Apr-26 - $ 2.00 $ 0.821 Series 23 Rights 258,333 22-Jun-21 23-Apr-26 - $ 3.00 $ 0.763 Series 24 Rights 258,334 22-Jun-21 23-Apr-26 - $ 4.00 $ 0.716
Inputs to Valuation Models Used for Options, Rights, and RSUs Granted	The tables below list the inputs to the valuation models used for Options, Rights, and RSUs granted by the Group during fiscal 2023 and fiscal 2022: 2023 2022 2021 Options RSUs and Rights that don’t have market-based vesting conditions Rights that have market-based vesting conditions Options RSUs and Rights that don’t have market-based vesting conditions Rights that have market-based vesting conditions Options Rights that have market-based vesting conditions Fair value at grant date (weighted average) A$0.491 A$0.782 A$0.322 A$0.775 A$1.115 A$0.784 A$0.217 A$0.673 Share price at grant date (weighted average) A$0.880 A$0.927 A$0.708 A$1.170 A$1.115 A$1.022 A$1.008 A$0.931 Vesting hurdle (30-day VWAP) (weighted average) - - A$3.49 - - A$3.65 - A$3.01 Exercise price (weighted average) A$1.03 - - A$1.33 - - A$0.24 - Expected life (weighted average) (1) 3.31 years 4.42 years 3.51 years 3.99 years 3.74 years 4.28 years 5.08 years 4.57 years Risk-free interest rate (weighted average) 3.310 % — 2.965 % 0.175% - 1.317 % 1.20 % 1.266 % Expected volatility (weighted average) (2) 87 % — 78 % 100% - 100 % 100 % 100 % Expected dividend yield (3) - - - - - - - - Notes: (1) The expected life is based on the expiry date of the options or rights. (2) The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. (3) The dividend yield reflects the assumption that the current dividend payout will remain unchanged.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2023
SEGMENT INFORMATION [Abstract]
Reconciliation of Non-current Assets by Geographical Location	(a) Reconciliation of non-current assets by geographical location 2023 2022 US$ US$ United States of America 10,048,804 3,819,215 10,048,804 3,819,215

FINANCIAL RISK MANAGEMENT OBJ_2

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Tables)	12 Months Ended
	Jun. 30, 2023
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES [Abstract]
Credit Risk	The carrying amount of the Group’s financial assets represents the maximum credit risk exposure, as represented below: 2023 2022 Note US$ US$ Cash and cash equivalents 5 11,937,941 5,672,551 Trade and other receivables 228,395 22,540 Other financial assets – 250,000 12,166,336 5,945,091
Contractual Maturities of Financial Liabilities	The contractual maturities of financial liabilities, including estimated interest payments, are provided below. There are no netting arrangements in respect of financial liabilities. ≤1 year 1-5 years ≥5 years Total contractual cash flows Carrying amount of liabilities US$ US$ US$ US$ US$ 2023 Financial liabilities Trade and other payables 1,180,984 - - 1,180,984 1,180,984 Lease liabilities 376,655 613,773 - 990,427 943,035 Other loans and borrowings 5,970 27,988 - 33,958 30,862 1,563,609 641,761 - 2,205,370 2,154,881 2022 Financial liabilities Trade and other payables 1,899,348 - - 1,899,348 1,899,348 Lease liabilities 167,619 421,142 - 588,761 506,573 Other loans and borrowings 7,811 31,242 4,556 43,609 36,457 2,074,778 452,384 4,556 2,531,718 2,442,378
Interest-Bearing Financial Instruments	At the reporting date, the interest rate profile of the Group’s interest-bearing financial instruments was: 2023 2022 Note US$ US$ Interest-bearing financial instruments Cash at bank and on hand 5 11,937,941 5,672,551 11,937,941 5,672,551
Disclosure of nature and extent of risks arising from financial instruments [line items]
Financial Instruments Denominated in Currencies Other Than Functional Currency	At the reporting date, the Group’s exposure to financial instruments denominated in currencies other than the functional currency of the group entity: Assets and liabilities denominated in currencies other than the functional currency of the group entity 2023 2022 Financial assets Cash and cash equivalents 8,498,094 2,040,266 Financial liabilities Trade and other payables (171,559 ) (438,282 ) Net exposure 8,326,535 1,601,984
Interest Rate Risk [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Sensitivity Analysis	This analysis assumes that all other variables, in particular foreign currency rates, remain constant. Profit or loss Equity +0.5% US$ -0.5% US$ +0.5% US$ -0.5% US$ 2023 Cash and cash equivalents 59,690 (59,690 ) 59,690 (59,690 ) 2022 Cash and cash equivalents 28,363 (28,363 ) 28,363 (28,363 )
Foreign Currency Risk [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Sensitivity Analysis	This analysis assumes that all other variables remain constant. Profit or loss Equity +10% US$ -10% US$ +10% US$ -10% US$ 2023 Group 832,653 (832,653 ) 832,653 (832,653 ) 2022 Group 160,198 (160,198 ) 160,198 (160,198 )

STATEMENT OF SIGNIFICANT ACCO_4

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Description of Business (Details)	Jun. 30, 2023 shares
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Number of ordinary shares listed on each securities exchange (in shares)	10

STATEMENT OF SIGNIFICANT ACCO_5

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Basis of Preparation (Details) - USD ($)		11 Months Ended		12 Months Ended
	Jul. 20, 2020	Jun. 30, 2021		Jun. 30, 2023		Jun. 30, 2022		Jul. 19, 2020
Basis of preparation [Abstract]
Net cash outflows from operating and investing activities				$ 21,569,980		$ 15,200,544
Cash and cash equivalents		$ 1,697,904		$ 11,937,941		$ 5,672,551		$ 0
Basic loss per share (in dollars per share)	$ (0.22)	$ (0.19)	[1]	$ (0.11)	[1]	$ (0.16)	[1]
Diluted loss per share (in dollars per share)	$ (0.22)	$ (0.19)	[1]	$ (0.11)	[1]	$ (0.16)	[1]
[1]Basic and diluted loss per share for the comparative period from July 20, 2020 to June 30, 2021 have been revised. Refer to Note 1(a) for further information.

STATEMENT OF SIGNIFICANT ACCO_6

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, New Standards And Amendments To Standards Issued But Not Effected (Details)	12 Months Ended
	Jun. 30, 2023
Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)
Application Date of Standard	Jan. 01, 2023
Application Date for the Group	Jul. 01, 2023
Definition of Accounting Estimates (Amendments to IAS 8) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Definition of Accounting Estimates (Amendments to IAS 8)
Application Date of Standard	Jan. 01, 2023
Application Date for the Group	Jul. 01, 2023
Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)
Application Date of Standard	Jan. 01, 2023
Application Date for the Group	Jul. 01, 2023
Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Classification of Liabilities as Current or Non-Current (Amendments to IAS 1)
Application Date of Standard	Jan. 01, 2024
Application Date for the Group	Jul. 01, 2024
Lease Liability in a Sale and Leaseback (Amendments to IFRS 16) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Lease Liability in a Sale and Leaseback (Amendments to IFRS 16)
Application Date of Standard	Jan. 01, 2024
Application Date for the Group	Jul. 01, 2024
Non-current Liabilities with Covenants (Amendments to IAS 1) [Member]
New standards, interpretations and amendments [Abstract]
Standard/Interpretation	Non-current Liabilities with Covenants (Amendments to IAS 1)
Application Date of Standard	Jan. 01, 2024
Application Date for the Group	Jul. 01, 2024

STATEMENT OF SIGNIFICANT ACCO_7

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Trade and Other Receivables (Details)	12 Months Ended
	Jun. 30, 2023
Trade and Other Receivables [Abstract]
Settlement period of trade receivables	30 days

STATEMENT OF SIGNIFICANT ACCO_8

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Property, Plant and Equipment (Details)	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Useful lives	5 years

STATEMENT OF SIGNIFICANT ACCO_9

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Trade and Other Payables (Details)	12 Months Ended
	Jun. 30, 2023
Trade and other payables [Abstract]
Settlement period of trade accounts payable	60 days

STATEMENT OF SIGNIFICANT ACC_10

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES, Operating Segments (Details)	12 Months Ended
	Jun. 30, 2023 Segment
Operating Segments [Abstract]
Number of operating segments	1

INCOME AND EXPENSES (Details)

INCOME AND EXPENSES (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Finance income [Abstract]
Interest income	$ 5,075	$ 139,697	$ 24,042
Net foreign exchange gain	0	354,772	377,003
Finance income	5,075	494,469	401,045
Finance costs [Abstract]
Interest expense	(3,097)	(88,138)	(45,541)
Other finance costs	(4,395)	0	(6,734)
Total finance costs	(7,492)	(88,138)	(52,275)
Other income and expenses [Abstract]
Other income	0	60,470	0
Loss on derecognition of financial asset	0	(250,000)	0
Cost of listing on reverse acquisition	(5,141,126)	0	0
Other income and expenses	(5,141,126)	(189,530)	0
Depreciation and amortisation [Abstract]
Amortisation of right-of-use assets	(8,364)	(249,387)	(119,706)
Depreciation of property, plant and equipment	(960)	(177,147)	(33,728)
Total depreciation and amortisation	(9,324)	(426,534)	(153,434)
Employee benefits expense [Abstract]
Wages and salaries	(509,474)	(4,714,673)	(2,739,427)
Employee benefits	(44,325)	(808,717)	(376,974)
Post-employment benefits	(8,929)	(134,074)	(67,496)
Share-based payment expenses	(4,084,764)	(2,589,413)	(8,340,328)
Total employee benefits expense	$ (4,647,492)	$ (8,246,877)	$ (11,524,225)

INCOME TAX, Profit or Loss and

INCOME TAX, Profit or Loss and Reconciliation Between Tax Expenses and Loss Before Income Tax (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Current income tax: [Abstract]
Current income tax benefit in respect of the current year	$ 0	$ 0	$ 0
Deferred income tax: [Abstract]
Origination and reversal of temporary differences	0	0	0
Income tax expense reported in profit or loss	0	0	0
Reconciliation between tax expense and accounting loss before income tax [Abstract]
Accounting loss before income tax	(13,230,837)	(17,444,754)	(21,521,237)
At the Australian income tax rate of 30%	(3,969,251)	(5,233,426)	(6,456,371)
Effect of lower income tax rate in the United States	124,391	488,952	433,351
Expenditure not allowable for income tax purposes	2,942,127	870,584	2,502,099
Exchange differences	(5,365)	5,329	30,731
Adjustments in respect of deferred tax of previous years	0	(182,314)	174,258
Effect of deferred tax assets not brought to account	908,098	4,050,875	3,315,932
Income tax expense reported in profit or loss	$ 0	$ 0	$ 0
Corporate tax rate	30%	30%	30%

INCOME TAX, Deferred Tax Assets

INCOME TAX, Deferred Tax Assets and Liabilities (Details) - USD ($)		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Deferred Tax Liabilities [Abstract]
Deferred tax assets used to offset deferred tax liabilities		$ (305,000)	$ (121,755)	$ (142,128)
Deferred tax liability (asset)		0	0	0
Deferred Tax Assets [Abstract]
Deferred tax assets used to offset deferred tax liabilities		(305,000)	(121,755)	(142,128)
Deferred tax assets acquired on reverse acquisition not brought to account	[1]	0	0	(410,028)
Other deferred tax assets not brought to account	[1]	(8,705,485)	(4,634,058)	(908,098)
Deferred tax liability (asset)		0	0	0
Right-of-use assets [Member]
Deferred Tax Liabilities [Abstract]
Deferred tax liabilities		305,000	121,755	142,128
Accrued Expenditure [Member]
Deferred Tax Assets [Abstract]
Deferred tax assets		139,113	22,500	53,997
Provision [Member]
Deferred Tax Assets [Abstract]
Deferred tax assets		21,956	12,125	2,893
Lease Liabilities [Member]
Deferred Tax Assets [Abstract]
Deferred tax assets		246,832	132,393	142,695
Capital Allowances [Member]
Deferred Tax Assets [Abstract]
Deferred tax assets		3,241,541	2,535,077	0
Tax Losses Available to Offset Against Future Taxable Income [Member]
Deferred Tax Assets [Abstract]
Deferred tax assets		$ 5,361,043	$ 2,053,718	$ 1,260,669
[1]The benefit of deferred tax assets not brought to account will only be subsequently recognised if: (a) future assessable income is derived of a nature and of an amount sufficient to enable the benefit to be realised; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realising the benefit.

DIVIDENDS PAID OR PROVIDED FO_2

DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES [Abstract]
Dividends paid	$ 0	$ 0	$ 0
Dividends proposed	$ 0	$ 0	$ 0

CASH AND CASH EQUIVALENTS (Deta

CASH AND CASH EQUIVALENTS (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Jul. 19, 2020
Cash and Cash equivalents and Reconciliation of Loss Before Income Tax to Net Cash Flows from Operations [Abstract]
Cash at bank and on hand	$ 1,697,904	$ 11,937,941	$ 5,672,551
Cash and cash equivalents	1,697,904	11,937,941	5,672,551	$ 0
Reconciliation of loss before income tax to net cash flows from operations [Abstract]
Net loss for the year	(13,230,837)	(17,444,754)	(21,521,237)
Adjustment for non-cash income and expense items [Abstract]
Share-based payments expense	4,084,764	2,589,413	8,340,328
Amortisation of right-of-use assets	8,364	249,387	119,706
Depreciation of property, plant and equipment	960	177,147	33,728
Net foreign exchange loss/(gain)	0	(354,772)	(377,003)
Loss on derecognition of financial asset	0	250,000	0
Lease modifications	0	0	(2,112)
Cost of listing on reverse acquisition	5,141,126	0	0
Changes in assets and liabilities [Abstract]
Increase in receivables and prepayments	(34,405)	(650,067)	(98,797)
(Decrease)/increase in payables and provisions	472,003	(680,748)	1,371,310
Net cash flows used in operating activities	$ (3,558,025)	$ (15,864,394)	$ (12,134,077)

PREPAYMENTS (Details)

PREPAYMENTS (Details)		12 Months Ended
		Jun. 30, 2023 USD ($) Patent	Jul. 31, 2024 USD ($)	Jan. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jan. 31, 2023 USD ($)	Jun. 30, 2022 USD ($)
Current [Abstract]
Other prepayments		$ 588,395					$ 144,183
Total current prepayments		588,395					144,183
Non-current [Abstract]
Blacksand option prepayments	[1]	3,000,000					0
Total non-current prepayments		3,000,000					0
Total prepayments		3,588,395					$ 144,183
Blacksand [Member]
Non-current [Abstract]
Additional amount to be paid upon exercise of option to purchase		$ 6,000,000
Blacksand [Member] | Bottom of range [member]
Non-current [Abstract]
Number of global patents owned | Patent		40
Blacksand [Member] | Option Period One [Member]
Non-current [Abstract]
Additional amount to be paid upon exercise of option to purchase						$ 1,500,000
Blacksand [Member] | Option Period Two [Member]
Non-current [Abstract]
Additional amount to be paid upon exercise of option to purchase					$ 1,500,000
Blacksand [Member] | Option Period Three [Member]
Non-current [Abstract]
Additional amount to be paid upon exercise of option to purchase				$ 1,500,000
Blacksand [Member] | Option Period Four [Member]
Non-current [Abstract]
Additional amount to be paid upon exercise of option to purchase			$ 1,500,000
[1]At June 30, 2023, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. The Group can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable by January 2023, July 2023, January 2024 and July 2024). These prepayments represent the first two option payments to Blacksand, paid in December 2022 and June 2023. Refer Note 21 for further details.

EXPLORATION AND EVALUATION AS_3

EXPLORATION AND EVALUATION ASSETS (Details)		12 Months Ended
		Jun. 30, 2023 USD ($) a		Jun. 30, 2022 USD ($)
Exploration And Evaluation Assets [Roll Forward]
Carrying amount, beginning balance		$ 2,431,229
Carrying amount, ending balance		3,059,021		$ 2,431,229
Titan Project [Member]
Exploration And Evaluation Assets [Roll Forward]
Carrying amount, beginning balance	[1]	2,431,229	[2]	504,750
Additions	[1]	627,792		1,926,479
Carrying amount, ending balance	[1],[2]	$ 3,059,021		$ 2,431,229
Area of land | a		11,071
Area of land owned | a		453
Area of land subject to exclusive option agreements | a		10,618
[1]At June 30, 2023, the Titan Project comprised of approximately 11,071 acres of surface and associated mineral rights in Tennessee prospective for heavy mineral sands, including titanium, rare earth minerals, high grade silica sand, and zircon, of which approximately 453 acres are owned and approximately 10,618 acres are subject to exclusive option agreements. These exclusive option agreements, upon exercise, allow the Group to lease, or in some cases purchase, the surface property and associated mineral rights.[2]The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		$ 1,387,986	$ 539,619
Additions		3,028,331	1,030,176
Modifications			(28,375)
Depreciation and amortization	$ (9,324)	(426,534)	(153,434)
Carrying amount, ending balance	539,619	3,989,783	1,387,986
At Cost [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		1,550,144
Carrying amount, ending balance		4,578,475	1,550,144
Accumulated Depreciation [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		(162,158)
Carrying amount, ending balance		(588,692)	(162,158)
Plant and Equipment [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		922,118	65,858
Additions		2,077,794	889,988
Modifications			0
Depreciation and amortization		(177,147)	(33,728)
Carrying amount, ending balance	65,858	2,822,765	922,118
Plant and Equipment [Member] | At Cost [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		956,805
Carrying amount, ending balance		3,034,599	956,805
Plant and Equipment [Member] | Accumulated Depreciation [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		(34,687)
Carrying amount, ending balance		(211,834)	(34,687)
Right-of-use Assets [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		465,868	473,761
Additions		950,537	140,188
Modifications			(28,375)
Depreciation and amortization		(249,387)	(119,706)
Carrying amount, ending balance	$ 473,761	1,167,018	465,868
Right-of-use Assets [Member] | At Cost [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		593,339
Carrying amount, ending balance		1,543,876	593,339
Right-of-use Assets [Member] | Accumulated Depreciation [Member]
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount, beginning balance		(127,471)
Carrying amount, ending balance		$ (376,858)	$ (127,471)

TRADE AND OTHER PAYABLES (Detai

TRADE AND OTHER PAYABLES (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current [Abstract]
Trade payables	$ 711,011	$ 1,677,757
Accruals	455,241	196,450
Payroll liabilities	14,732	25,141
Total trade and other current payables	$ 1,180,984	$ 1,899,348

LOANS AND BORROWINGS, Loans and

LOANS AND BORROWINGS, Loans and Borrowings (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current [Abstract]
Lease liabilities	$ 376,655	$ 128,653
Other loans and borrowings	5,971	5,594
Total current loans and borrowings	382,626	134,247
Non-current [Abstract]
Lease liabilities	567,796	377,920
Other loans and borrowings	24,892	30,863
Total non-current loans and borrowings	592,688	408,783
Total loans and borrowings	$ 975,314	$ 543,030

LOANS AND BORROWINGS, Reconcili

LOANS AND BORROWINGS, Reconciliation of Loans and Borrowings (Details)	12 Months Ended
	Jun. 30, 2023 USD ($)
Reconciliation of Change in Borrowings [Abstract]
Balance	$ 543,030
Additions	950,538
Repayments	(518,254)
Balance	975,314
Lease Liabilities [Member]
Reconciliation of Change in Borrowings [Abstract]
Balance	506,573
Additions	950,538
Repayments	(512,660)
Balance	944,451
Other Loans and Borrowings [Member]
Reconciliation of Change in Borrowings [Abstract]
Balance	36,457
Additions	0
Repayments	(5,594)
Balance	$ 30,863

LEASES (Details)

LEASES (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
LEASES [Abstract]
Amortisation of right-of-use assets	$ (8,364)	$ (249,387)	$ (119,706)
Interest expense on lease liabilities		(78,040)	(44,512)
Net amount recognised in profit or loss		$ (327,427)	$ (164,218)

CONTRIBUTED EQUITY, Issued Capi

CONTRIBUTED EQUITY, Issued Capital (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Issued capital [abstract]
Issued capital 193,493,973 (2022: 140,288,491) fully paid ordinary shares	$ 58,764,248	$ 29,782,268
Contributed Equity [Member]
Issued capital [abstract]
Issued capital 193,493,973 (2022: 140,288,491) fully paid ordinary shares	$ 58,764,248	$ 29,782,268	$ 10,255,369
Number of shares issued and fully paid ordinary shares (in shares)	193,493,973	140,288,491

CONTRIBUTED EQUITY, Movements i

CONTRIBUTED EQUITY, Movements in Issued Capital (Details)	11 Months Ended	12 Months Ended
	Jun. 30, 2021 USD ($) shares	Jun. 30, 2023 USD ($) vote qtr Shareholder shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2023 AUD ($)
Movements in Issued Capital [Abstract]
Opening balance | $		$ 29,782,268
Issue of shares - exercise of options | $		284,645	$ 2,261,225
Issue of shares - conversion of RSUs | $		0
Issue of shares to consultant | $		0
Share issue costs | $	$ (85,467)	(1,511,182)	(430,805)
Closing balance | $		$ 58,764,248	29,782,268
Contributed Equity [Member]
Movements in Issued Capital [Abstract]
Opening balance (in shares)		140,288,491
Opening balance | $		$ 29,782,268	10,255,369
Issue of shares - share placement | $		29,637,300	17,604,000
Issue of shares - exercise of options | $		477,156	2,353,704
Issue of shares - conversion of RSUs | $		167,487
Issue of shares - conversion of performance rights | $		216,007
Issue of shares to consultant | $		350,000
Share issue costs | $	(85,467)	$ (1,865,970)	$ (430,805)
Closing balance (in shares)		193,493,973	140,288,491
Closing balance | $	$ 10,255,369	$ 58,764,248	$ 29,782,268
Meetings of Members [Abstract]
Quorum number of shareholders | Shareholder		2
Voting [Abstract]
Number of votes for each eligible voter present | vote		1
Number of votes eligible for each fully paid share | vote		1
Changes to the Constitution [Abstract]
Minimum quarters of present meeting members required to amend Company Constitution | qtr		3
Minimum written notice required to propose special resolution		28 days
Performance Shares [Abstract]
Conversion of performance shares into ordinary shares by applicable expiry date (in shares)		60
Contributed Equity [Member] | Bottom of Range [Member]
Performance Shares [Abstract]
Net present value of assets | $				$ 200,000,000
Contributed Equity [Member] | Ordinary Shares [Member]
Movements in Issued Capital [Abstract]
Opening balance (in shares)		140,288,491	105,105,787
Issue of shares - share placement (in shares)		50,000,000	20,000,000
Issue of shares - exercise of options (in shares)		2,102,363	15,182,704
Issue of shares - conversion of RSUs (in shares)		200,001
Issue of shares - conversion of performance rights (in shares)		215,495
Issue of shares to consultant (in shares)		687,623
Closing balance (in shares)	105,105,787	193,493,973	140,288,491
Contributed Equity [Member] | Performance Shares [Member]
Performance Shares [Abstract]
Issue of equity through acquisition (in shares)		39,600,000
Contributed Equity [Member] | Class A [Member]
Movements in Issued Capital [Abstract]
Opening balance (in shares)		19,800,000	19,800,000
Issue of shares - share placement (in shares)		0	0
Issue of shares - exercise of options (in shares)		0
Issue of shares - conversion of RSUs (in shares)		0
Closing balance (in shares)	19,800,000	19,800,000	19,800,000
Performance Shares [Abstract]
Issue of equity through acquisition (in shares)		19,800,000
Number of ordinary shares to be converted from each performance shares		1
Conversion of performance shares into ordinary shares by applicable expiry date (in shares)		30
Contributed Equity [Member] | Class B [Member]
Movements in Issued Capital [Abstract]
Opening balance (in shares)		19,800,000	19,800,000
Issue of shares - share placement (in shares)		0	0
Issue of shares - exercise of options (in shares)		0
Issue of shares - conversion of RSUs (in shares)		0
Closing balance (in shares)	19,800,000	19,800,000	19,800,000
Performance Shares [Abstract]
Issue of equity through acquisition (in shares)		19,800,000
Number of ordinary shares to be converted from each performance shares		1
Conversion of performance shares into ordinary shares by applicable expiry date (in shares)		30

RESERVES, Summary (Details)

RESERVES, Summary (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
RESERVES [Abstract]
Share based payments reserve	$ 15,004,052		$ 12,985,856
Foreign currency translation reserve	(1,008,244)	$ (596,331)	(596,331)	$ (2,419)
Total Reserve	$ 13,995,808		$ 12,389,525

RESERVES, Movements in Share-ba

RESERVES, Movements in Share-based Payments Reserve (Details)	11 Months Ended	12 Months Ended
	Jun. 30, 2021 USD ($) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares
Number of Performance Rights and Restricted Stock Units [Abstract]
Opening balance, Share-based payments reserve | $		$ 12,985,856
Conversion of RSUs | $		0
Issue of shares to consultant | $		0
Exercise of options | $		(284,645)	$ (2,261,225)
Share-based payments expense | $	$ 4,084,764	2,589,413	8,340,328
Closing balance, share-based payments reserve | $		$ 15,004,052	$ 12,985,856
Listed Options [Member]
Number of Options [Abstract]
Outstanding at beginning of period (in shares)		0	12,624,214
Grant of employee incentive securities (in shares)		0	0
Grant of options to financial advisor (in shares)		0
Exercise of options (in shares)	(3,069,120)	0	(12,606,704)
Issue of shares to a consultant (in shares)		0
Lapse of employee incentive securities (in shares)		0
Expiry of options (in shares)	0	0	(17,510)
Outstanding at end of period (in shares)	12,624,214	0	0
Unlisted Options [Member]
Number of Options [Abstract]
Outstanding at beginning of period (in shares)		23,824,000	25,800,000
Grant of employee incentive securities (in shares)		424,372	600,000
Grant of options to financial advisor (in shares)		1,000,000
Exercise of options (in shares)	(1,350,000)	(2,237,000)	(2,576,000)
Issue of shares to a consultant (in shares)		0
Lapse of employee incentive securities (in shares)		0
Expiry of options (in shares)			0
Outstanding at end of period (in shares)	25,800,000	23,011,372	23,824,000
Performance Rights [Member]
Number of Performance Rights and Restricted Stock Units [Abstract]
Opening balance (in shares)		27,620,000	16,325,000
Grant of employee incentive securities (in shares)		1,535,000	11,295,000
Conversion of RSUs (in shares)		(329,000)
Conversion of performance rights (in shares)		0
Lapse of employee incentive securities (in shares)		(80,000)
Closing balance (in shares)	16,325,000	28,746,000	27,620,000
Restricted Stock Units [Member]
Number of Performance Rights and Restricted Stock Units [Abstract]
Opening balance (in shares)		600,000	0
Grant of employee incentive securities (in shares)		424,372	600,000
Conversion of RSUs (in shares)		0
Conversion of performance rights (in shares)		(200,001)
Lapse of employee incentive securities (in shares)		0
Closing balance (in shares)	0	824,371	600,000
Share Based Payments Reserve [Member]
Number of Performance Rights and Restricted Stock Units [Abstract]
Opening balance, Share-based payments reserve | $		$ 12,985,856	$ 4,738,007
Grant of employee incentive securities | $		0	0
Grant of options to financial advisor | $		354,788
Conversion of RSUs | $		(167,487)
Conversion of performance rights | $		(216,007)
Exercise of options | $		(192,511)	(92,479)
Expiration of options | $			0
Share-based payments expense | $		2,589,413	8,340,328
Closing balance, share-based payments reserve | $	$ 4,738,007	15,004,052	$ 12,985,856
Share Based Payments Reserve [Member] | Listed Options [Member]
Number of Performance Rights and Restricted Stock Units [Abstract]
Issue of shares to consultant | $		$ (350,000)

RESERVES, Terms and Conditions

RESERVES, Terms and Conditions of Unlisted Options (Details)	12 Months Ended
	Jun. 30, 2023 shares $ / shares
Unlisted Options [Member]
Terms and conditions of unlisted options [Abstract]
Share based payment arrangement subscription rights (in shares)	1
Unlisted Options [Member] | Exercisable at A$0.20 Expiring each on or before December 31, 2023 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	2,550,000
Exercise price (in dollars per share) | $ / shares	$ 0.2
Unlisted Options [Member] | Exercisable at A$0.20 Expiring each on or before December 1, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	3,975,000
Exercise price (in dollars per share) | $ / shares	$ 0.2
Unlisted Options [Member] | Exercisable at A$0.25 Expiring each on or before December 31, 2023 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	4,612,000
Exercise price (in dollars per share) | $ / shares	$ 0.25
Unlisted Options [Member] | Exercisable at A$0.45 Expiring each on or before December 31, 2023 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	975,000
Exercise price (in dollars per share) | $ / shares	$ 0.45
Unlisted Options [Member] | Exercisable at A$0.55 Expiring each on or before December 31, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	875,000
Exercise price (in dollars per share) | $ / shares	$ 0.55
Unlisted Options [Member] | Exercisable at A$0.87 Expiring each on or before December 5, 2026 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	424,372
Exercise price (in dollars per share) | $ / shares	$ 0.87
Unlisted Options [Member] | Exercisable at A$1.10 Expiring each on or before September 14, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	1,000,000
Exercise price (in dollars per share) | $ / shares	$ 1.1
Unlisted Options [Member] | Exercisable at A$1.33 Expiring each on or before September 9, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	600,000
Exercise price (in dollars per share) | $ / shares	$ 1.33
Class A Performance Unlisted Options [Member] | Exercisable at A$0.20 Expiring each on or before December 1, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	4,000,000
Exercise price (in dollars per share) | $ / shares	$ 0.2
Class B Performance Unlisted Options [Member] | Exercisable at A$0.20 Expiring each on or before December 1, 2025 [Member]
Terms and conditions of unlisted options [Abstract]
Options exercisable (in shares)	4,000,000
Exercise price (in dollars per share) | $ / shares	$ 0.2

RESERVES, Terms and Condition_2

RESERVES, Terms and Conditions of Performance Rights (Details) - Performance Rights [Member]	11 Months Ended	12 Months Ended
	Jun. 30, 2021 shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares
Terms and conditions of performance rights [Abstract]
Number of shares converted upon vesting (in shares)		1
Rights vest (in shares)	2,000,000	329,000	0
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		6,101,665
Volume weighted average price (in dollars per share) | $ / shares		$ 2
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member] | Expiring April 23, 2024 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		175,000
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member] | Expiring December 22, 2024 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		25,000
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member] | Expiring March 1, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		150,000
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member] | Expiring April 23, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		5,701,665
Vesting upon Achieving a 30-day VWAP of $2.00 Per Share [Member] | Expiring December 22, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		50,000
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		7,661,667
Volume weighted average price (in dollars per share) | $ / shares		$ 3
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member] | Expiring April 23, 2024 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		275,000
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member] | Expiring March 1, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		150,000
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member] | Expiring April 23, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		7,111,667
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member] | Expiring December 22, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		100,000
Vesting upon Achieving a 30-day VWAP of $3.00 Per Share [Member] | Expiring December 22, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		25,000
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		12,746,668
Volume weighted average price (in dollars per share) | $ / shares		$ 4
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring April 23, 2024 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		125,000
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring March 1, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		150,000
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring April 23, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		11,246,668
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring December 22, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		175,000
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring December 22, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		50,000
Vesting upon Achieving a 30-day VWAP of $4.00 Per Share [Member] | Expiring April 6, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		1,000,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		2,236,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring April 23, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		200,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring December 22, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		265,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring December 22, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		261,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring April 6, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		1,000,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring December 31, 2025 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		55,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring December 31, 2026 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		55,000
Vesting upon Achieving Various (Non-market Based) Performance Conditions [Member] | Expiring January 31, 2027 [Member]
Terms and conditions of performance rights [Abstract]
Rights vest (in shares)		400,000

RESERVES, Terms and Condition_3

RESERVES, Terms and Conditions of Restricted Stock Units (Details) - Restricted Stock Units [Member]	11 Months Ended	12 Months Ended
	Jun. 30, 2021 shares	Jun. 30, 2023 shares	Jun. 30, 2022 shares
Terms and conditions of restricted stock units [Abstract]
Number of shares converted upon vesting (in shares)		1
Number of shares vest upon achieving service based condition (in shares)	0	200,001	0
Expiring September 9, 2025 [Member]
Terms and conditions of restricted stock units [Abstract]
Number of shares vest upon achieving service based condition (in shares)		399,999
Expiring December 5, 2026 [Member]
Terms and conditions of restricted stock units [Abstract]
Number of shares vest upon achieving service based condition (in shares)		424,372

RESERVES, Movements in Foreign

RESERVES, Movements in Foreign Currency Translation Reserve (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
RESERVES [Abstract]
Balance at start of year		$ (596,331)
Exchange differences arising on translation into presentation currency	$ (2,419)	(411,913)	$ (593,912)
Balance at end of year		$ (1,008,244)	$ (596,331)

ACCUMULATED LOSSES (Details)

ACCUMULATED LOSSES (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
ACCUMULATED LOSSES [Abstract]
Balance at start of year		$ (34,752,074)	$ (13,230,837)
Net loss for the year	$ (13,230,837)	(17,444,754)	(21,521,237)
Balance at June 30	$ (13,230,837)	$ (52,196,828)	$ (34,752,074)

LOSS PER SHARE (Details)

LOSS PER SHARE (Details)		3 Months Ended	11 Months Ended		12 Months Ended
	Jul. 20, 2020 $ / shares	Sep. 15, 2023 shares	Jun. 30, 2021 USD ($) $ / shares shares		Jun. 30, 2023 USD ($) $ / shares shares		Jun. 30, 2022 USD ($) $ / shares shares
Loss per Share [Abstract]
Basic loss per share (in dollars per share) | $ / shares	$ (0.22)		$ (0.19)	[1]	$ (0.11)	[1]	$ (0.16)	[1]
Diluted loss per share (in dollars per share) | $ / shares	$ (0.22)		$ (0.19)	[1]	$ (0.11)	[1]	$ (0.16)	[1]
Income and share data used in calculations of basic earnings per share [Abstract]
Net loss | $			$ (13,230,837)		$ (17,444,754)		$ (21,521,237)
Net loss used in calculating basic and dilutive earnings per share | $			$ (13,230,837)		$ (17,444,754)		$ (21,521,237)
Weighted average number of ordinary shares used in calculating basic and dilutive earnings per share [Abstract]
Basic (in shares)			68,798,762		168,029,357		134,609,413
Dilutive (in shares)			68,798,762		168,029,357		134,609,413
Ordinary Shares [Member]
Non-Dilutive Securities [Abstract]
Anti-dilutive effect of share options on number of ordinary shares (in shares)			94,349,214		92,181,743		91,644,000
Ordinary Shares [Member] | Subsequent Events [Member]
Conversions, Calls, Subscriptions or Issues [Abstract]
Issued (in shares)		1,225,000
Unlisted Options [Member]
Non-Dilutive Securities [Abstract]
Anti-dilutive effect of share options on number of ordinary shares (in shares)					23,011,372
Performance Rights [Member]
Non-Dilutive Securities [Abstract]
Anti-dilutive effect of share options on number of ordinary shares (in shares)					28,746,000
Performance Rights [Member] | Subsequent Events [Member]
Conversions, Calls, Subscriptions or Issues [Abstract]
Issued (in shares)		50,000
Forfeited/cancelled (in shares)		80,000
Restricted Stock Units [Member]
Non-Dilutive Securities [Abstract]
Anti-dilutive effect of share options on number of ordinary shares (in shares)					824,371
Performance Shares [Member]
Non-Dilutive Securities [Abstract]
Anti-dilutive effect of share options on number of ordinary shares (in shares)					39,600,000
[1]Basic and diluted loss per share for the comparative period from July 20, 2020 to June 30, 2021 have been revised. Refer to Note 1(a) for further information.

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Key Management Personnel [Abstract]
Short-term employee benefits	$ 275,246	$ 2,109,813	$ 1,503,275
Post-employment benefits	6,079	47,502	25,114
Share-based payments	3,681,159	1,650,382	7,146,121
Total compensation	3,962,484	3,807,697	8,674,510
Loans provided to key management personnel	0	0	0
Loans provided from key management personnel	$ 0	0	$ 0
Performance Industries, Inc [Member]
Key Management Personnel [Abstract]
Payment for provision of services in relation to business development		$ 145,055
Hyperion Metals (Australia) Pty Ltd [Member]
Subsidiaries [Abstract]
Country of Incorporation		Australia
Equity Interest	100%	100%	100%
IperionX Critical Minerals LLC [Member]
Subsidiaries [Abstract]
Country of Incorporation		United States
Equity Interest	100%	100%	100%
IperionX Technology LLC [Member]
Subsidiaries [Abstract]
Country of Incorporation		United States
Equity Interest	100%	100%	100%
IperionX Inc. [Member]
Subsidiaries [Abstract]
Country of Incorporation		United States
Equity Interest	0%	100%	100%
Calatos Pty Ltd LLC [Member]
Subsidiaries [Abstract]
Country of Incorporation		United States
Equity Interest	100%	100%	100%

SHARE-BASED PAYMENTS, Recognise

SHARE-BASED PAYMENTS, Recognised Share-based Payment Expense (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Equity Settled Share Based Payments [Abstract]
Expense arising from staff remuneration arrangements	$ (4,084,764)	$ (2,589,413)	$ (8,340,328)
Expense arising from cost of listing on reverse acquisition	(5,141,126)	0	0
Total expense arising from equity-settled share-based payment transactions	$ (9,225,890)	$ (2,589,413)	$ (8,340,328)

SHARE-BASED PAYMENTS, Summary o

SHARE-BASED PAYMENTS, Summary of Securities Granted as Share-Based Payments (Details)	11 Months Ended	12 Months Ended
	Jun. 30, 2021 shares $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares
Number of Outstanding Instruments [Roll Forward]
Outstanding at beginning of year (in shares)	0	52,044,000	54,749,214
Outstanding at end of year (in shares)	54,749,214	52,581,743	52,044,000
Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of year (in dollars per share) | $ / shares	$ 0	$ 0.12	$ 0.19
Outstanding at end of year (in dollars per share) | $ / shares	$ 0.19	$ (0.14)	$ 0.12
Listed options [Member]
Number of Outstanding Instruments [Roll Forward]
Options exercised during the year (in shares)	(3,069,120)	0	(12,606,704)
Options expired during the year (in shares)	0	0	(17,510)
Recognition of legal acquirer (in shares)	15,693,334	0	0
Weighted Average Exercise Price [Roll Forward]
Options exercised during the year (in dollars per share) | $ / shares	$ (0.2)	$ 0	$ (0.2)
Options expired during the year (in dollars per share) | $ / shares	0	0	(0.2)
Recognition of legal acquirer (in dollars per share) | $ / shares	$ 0.2	$ 0	$ 0
Options [Member]
Number of Outstanding Instruments [Roll Forward]
Options granted during the year (in shares)	9,150,000	1,424,372	600,000
Options exercised during the year (in shares)	(1,350,000)	(2,237,000)	(2,576,000)
Options expired during the year (in shares)			0
Recognition of legal acquirer (in shares)	5,000,000	0	0
Options granted to vendors of legal acquiree (in shares)	13,000,000	0	0
Weighted Average Exercise Price [Roll Forward]
Options granted during the year (in dollars per share) | $ / shares	$ 0.31	$ 1.03	$ 1.33
Options exercised during the year (in dollars per share) | $ / shares	(0.24)	(0.26)	(0.22)
Recognition of legal acquirer (in dollars per share) | $ / shares	0.2	0	0
Options granted to vendors of legal acquiree (in dollars per share) | $ / shares	$ 0.2	$ 0	$ 0
Rights [Member]
Number of Outstanding Instruments [Roll Forward]
Rights/RSUs granted during the year (in shares)	16,325,000	1,535,000	11,295,000
Rights/RSUs converted during the year (in shares)	(2,000,000)	(329,000)	0
Rights lapsed during the year	0	(80,000)	0
Recognition of legal acquirer (in shares)	2,000,000	0	0
Weighted Average Exercise Price [Roll Forward]
Rights/RSUs granted during the year (in dollars per share) | $ / shares	$ 0	$ 0	$ 0
Rights/RSUs converted during the year (in dollars per share) | $ / shares	0	0	0
Rights lapsed during the year (in dollars per share) | $ / shares	0	0	0
Recognition of legal acquirer (in dollars per share) | $ / shares	$ 0	$ 0	$ 0
RSUs [Member]
Number of Outstanding Instruments [Roll Forward]
Rights/RSUs granted during the year (in shares)	0	424,372	600,000
Rights/RSUs converted during the year (in shares)	0	(200,001)	0
Weighted Average Exercise Price [Roll Forward]
Rights/RSUs granted during the year (in dollars per share) | $ / shares	$ 0	$ 0	$ 0
Rights/RSUs converted during the year (in dollars per share) | $ / shares	$ 0	$ 0	$ 0

SHARE-BASED PAYMENTS, Options,

SHARE-BASED PAYMENTS, Options, Rights and RSUs Granted as Share-Based Payments (Details)	11 Months Ended	12 Months Ended
	Jun. 30, 2021 AUD ($) shares $ / shares	Jun. 30, 2023 AUD ($) shares $ / shares	Jun. 30, 2022 AUD ($) shares $ / shares	Jul. 19, 2020 AUD ($)
Rights [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	16,325,000	1,535,000	11,295,000
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Rights [Member] | Series 1 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			200,000
Grant date			July 19, 2021
Expiry date			Dec. 22, 2024
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.93
Rights [Member] | Series 2 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			200,000
Grant date			July 19, 2021
Expiry date			Dec. 22, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.93
Rights [Member] | Series 3 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			200,000
Grant date			July 19, 2021
Expiry date			Dec. 22, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.93
Rights [Member] | Series 4 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		400,000	25,000
Grant date		August 8, 2022	July 19, 2021
Expiry date		Apr. 23, 2026	Apr. 23, 2026
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 3	$ 4
Fair value | $		$ 0.354	$ 0.71
Rights [Member] | Series 5 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		400,000	25,000
Grant date		August 8, 2022	July 19, 2021
Expiry date		Apr. 23, 2026	Apr. 23, 2024
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 4	$ 2
Fair value | $		$ 0.293	$ 0.699
Rights [Member] | Series 6 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	150,000	200,000	25,000
Grant date	March 3, 2021	August 8, 2022	July 19, 2021
Expiry date	Mar. 01, 2026	Apr. 23, 2026	Apr. 23, 2024
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 2	$ 0	$ 3
Fair value | $	$ 0.694	$ 0.675	$ 0.591
Rights [Member] | Series 7 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	150,000	10,000	1,000,000
Grant date	March 3, 2021	September 6, 2022	September 1, 2021
Expiry date	Mar. 01, 2026	Apr. 23, 2026	Apr. 23, 2026
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 3	$ 2	$ 3
Fair value | $	$ 0.643	$ 0.617	$ 1.195
Rights [Member] | Series 8 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	150,000	15,000	1,000,000
Grant date	March 3, 2021	September 6, 2022	September 1, 2021
Expiry date	Mar. 01, 2026	Apr. 23, 2026	Apr. 23, 2026
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 4	$ 3	$ 4
Fair value | $	$ 0.602	$ 0.496	$ 1.131
Rights [Member] | Series 9 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,000,000	35,000
Grant date	April 14, 2021	September 6, 2022
Expiry date	Apr. 23, 2026	Apr. 23, 2026
Exercise price (in dollars per share)	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 2	$ 4
Fair value | $	$ 0.745	$ 0.428
Rights [Member] | Series 10 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,000,000	10,000
Grant date	April 14, 2021	June 6, 2022
Expiry date	Apr. 23, 2026	Apr. 23, 2026
Exercise price (in dollars per share)	$ 0
Exercise price (in dollars per share)		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 3
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 2
Fair value | $	$ 0.693
Fair value | $		$ 0.556
Rights [Member] | Series 11 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,000,000	15,000	4,000
Grant date	April 14, 2021	June 6, 2022	October 11, 2021
Expiry date	Apr. 23, 2026	Apr. 23, 2026	Dec. 22, 2024
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 4	$ 3	$ 0
Fair value | $	$ 0.651	$ 0.46	$ 1.1
Rights [Member] | Series 12 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		20,000	6,000
Grant date		June 6, 2022	October 11, 2021
Expiry date		Apr. 23, 2026	Dec. 22, 2025
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 4	$ 0
Fair value | $		$ 0.39	$ 1.1
Rights [Member] | Series 13 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		10,000	10,000
Grant date		June 8, 2022	October 11, 2021
Expiry date		Dec. 31, 2024	Dec. 22, 2026
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 0	$ 0
Fair value | $		$ 0.78	$ 1.1
Rights [Member] | Series 14 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	125,000	10,000	40,000
Grant date	April 15, 2021	June 8, 2022	October 12, 2021
Expiry date	Apr. 23, 2024	Dec. 31, 2025	Dec. 22, 2024
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 2	$ 0	$ 0
Fair value | $	$ 0.599	$ 0.78	$ 1.07
Rights [Member] | Series 15 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	125,000	10,000	40,000
Grant date	April 15, 2021	June 8, 2022	October 12, 2021
Expiry date	Apr. 23, 2024	Dec. 31, 2026	Dec. 22, 2025
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 3	$ 0	$ 0
Fair value | $	$ 0.51	$ 0.78	$ 1.07
Rights [Member] | Series 16 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	125,000		40,000
Grant date	April 15, 2021		October 12, 2021
Expiry date	Apr. 23, 2024		Dec. 22, 2026
Exercise price (in dollars per share)	$ 0		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 4		$ 0
Fair value | $	$ 0.445		$ 1.07
Rights [Member] | Series 17 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,875,000	400,000	225,000
Grant date	April 15, 2021	February 1, 2023	October 14, 2021
Expiry date	Apr. 23, 2026	Jan. 31, 2027	Apr. 23, 2026
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 2	$ 0	$ 4
Fair value | $	$ 0.705	$ 0.88	$ 0.801
Rights [Member] | Series 18 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,875,000	25,000	25,000
Grant date	April 15, 2021	March 16, 2023	October 14, 2021
Expiry date	Apr. 23, 2026	Apr. 23, 2026	Apr. 23, 2024
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 3	$ 3	$ 2
Fair value | $	$ 0.654	$ 0.286	$ 0.79
Rights [Member] | Series 19 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	2,975,000	25,000	125,000
Grant date	April 15, 2021	March 16, 2023	October 14, 2021
Expiry date	Apr. 23, 2026	Apr. 23, 2026	Apr. 23, 2024
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 4	$ 4	$ 3
Fair value | $	$ 0.613	$ 0.219	$ 0.663
Rights [Member] | Series 20 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		175,000	15,000
Grant date		April 1, 2023	November 8, 2021
Expiry date		Apr. 23, 2026	Dec. 22, 2024
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 3	$ 0
Fair value | $		$ 0.321	$ 0.955
Rights [Member] | Series 21 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		175,000	15,000
Grant date		April 1, 2023	November 8, 2021
Expiry date		Apr. 23, 2026	Dec. 22, 2025
Exercise price (in dollars per share)		$ 0	$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 4	$ 0
Fair value | $		$ 0.247	$ 0.955
Rights [Member] | Series 22 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	258,333		15,000
Grant date	June 22, 2021		November 8, 2021
Expiry date	Apr. 23, 2026		Dec. 22, 2026
Exercise price (in dollars per share)	$ 0		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 2		$ 0
Fair value | $	$ 0.821		$ 0.955
Rights [Member] | Series 23 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	258,333		30,000
Grant date	June 22, 2021		November 15, 2021
Expiry date	Apr. 23, 2026		Dec. 31, 2024
Exercise price (in dollars per share)	$ 0		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 3		$ 0
Fair value | $	$ 0.763		$ 0.99
Rights [Member] | Series 24 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	258,334		30,000
Grant date	June 22, 2021		November 15, 2021
Expiry date	Apr. 23, 2026		Dec. 31, 2025
Exercise price (in dollars per share)	$ 0		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 4		$ 0
Fair value | $	$ 0.716		$ 0.99
Rights [Member] | Series 25 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			30,000
Grant date			November 15, 2021
Expiry date			Dec. 31, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.99
Rights [Member] | Series 26 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			3,500,000
Grant date			November 25, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.644
Rights [Member] | Series 27 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			250,000
Grant date			December 6, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 2
Fair value | $			$ 0.703
Rights [Member] | Series 28 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			250,000
Grant date			December 6, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 3
Fair value | $			$ 0.642
Rights [Member] | Series 29 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			500,000
Grant date			December 6, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.594
Rights [Member] | Series 30 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			50,000
Grant date			December 15, 2021
Expiry date			Dec. 22, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.752
Rights [Member] | Series 31 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			314,998
Grant date			December 15, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 2
Fair value | $			$ 0.728
Rights [Member] | Series 32 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			100,000
Grant date			December 15, 2021
Expiry date			Dec. 22, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.7
Rights [Member] | Series 33 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			315,001
Grant date			December 15, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 3
Fair value | $			$ 0.665
Rights [Member] | Series 34 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			150,000
Grant date			December 15, 2021
Expiry date			Dec. 22, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.658
Rights [Member] | Series 35 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			325,001
Grant date			December 15, 2021
Expiry date			Apr. 23, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.616
Rights [Member] | Series 36 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			30,000
Grant date			January 1, 2022
Expiry date			Dec. 31, 2024
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.91
Rights [Member] | Series 37 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			30,000
Grant date			January 1, 2022
Expiry date			Dec. 31, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.91
Rights [Member] | Series 38 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			30,000
Grant date			January 1, 2022
Expiry date			Dec. 31, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.91
Rights [Member] | Series 39 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			50,000
Grant date			January 1, 2022
Expiry date			Dec. 22, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.634
Rights [Member] | Series 40 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			25,000
Grant date			January 31, 2022
Expiry date			Dec. 22, 2026
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.695
Rights [Member] | Series 41 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			25,000
Grant date			January 31, 2022
Expiry date			Dec. 22, 2024
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 2
Fair value | $			$ 0.684
Rights [Member] | Series 42 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			25,000
Grant date			January 31, 2022
Expiry date			Dec. 22, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 3
Fair value | $			$ 0.677
Rights [Member] | Series 43 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			1,000,000
Grant date			March 29, 2022
Expiry date			Apr. 06, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 1.235
Rights [Member] | Series 44 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			1,000,000
Grant date			March 29, 2022
Expiry date			Apr. 06, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 4
Fair value | $			$ 0.84
RSUs [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	0	424,372	600,000
Exercise price (in dollars per share)	$ 0	$ 0	$ 0
RSUs [Member] | Series 3 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		424,372
Grant date		November 25, 2022
Expiry date		Dec. 05, 2026
Exercise price (in dollars per share)		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 0
Fair value | $		$ 0.74
RSUs [Member] | Series 9 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			600,000
Grant date			September 13, 2021
Expiry date			Sep. 09, 2025
Exercise price (in dollars per share)			$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 1.17
Options [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Exercise price (in dollars per share)	0.24	$ 1.03	$ 1.33
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0	$ 0	$ 0
Fair value | $		$ 0.491	$ 0.775	$ 0.217
Options [Member] | Series 1 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	7,000,000	1,000,000
Grant date	December 1, 2020	September 14, 2022
Expiry date	Dec. 31, 2023	Sep. 14, 2025
Exercise price (in dollars per share)		$ 1.1
Exercise price (in dollars per share)	$ 0.25
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $		$ 0.519
Fair value | $	$ 0.163
Options [Member] | Series 2 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	5,000,000	424,372
Grant date	December 1, 2020	November 25, 2022
Expiry date	Dec. 01, 2025	Dec. 05, 2026
Exercise price (in dollars per share)		$ 0.87
Exercise price (in dollars per share)	$ 0.2
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $		$ 0.424
Fair value | $	$ 0.201
Options [Member] | Series 3 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	4,000,000
Grant date	December 1, 2020
Expiry date	Dec. 01, 2025
Exercise price (in dollars per share)	$ 0.2
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.201
Options [Member] | Series 4 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	4,000,000
Grant date	December 1, 2020
Expiry date	Dec. 01, 2025
Exercise price (in dollars per share)	$ 0.2
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.201
Options [Member] | Series 5 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	5,000,000
Grant date	December 1, 2020
Expiry date	Dec. 31, 2023
Exercise price (in dollars per share)	$ 0.2
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.174
Options [Member] | Series 10 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares			600,000
Grant date			September 13, 2021
Expiry date			Sep. 09, 2025
Exercise price (in dollars per share)			$ 1.33
Vesting Hurdle (30-day VWAP) (in dollars per share)			$ 0
Fair value | $			$ 0.775
Options [Member] | Series 12 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	875,000
Grant date	April 14, 2021
Expiry date	Dec. 31, 2023
Exercise price (in dollars per share)	$ 0.45
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.605
Options [Member] | Series 13 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	875,000
Grant date	April 14, 2021
Expiry date	Dec. 31, 2023
Exercise price (in dollars per share)	$ 0.55
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.575
Options [Member] | Series 20 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	200,000
Grant date	April 15, 2021
Expiry date	Dec. 31, 2023
Exercise price (in dollars per share)	$ 0.45
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.57
Options [Member] | Series 21 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares	200,000
Grant date	April 15, 2021
Expiry date	Dec. 31, 2023
Exercise price (in dollars per share)	$ 0.55
Vesting Hurdle (30-day VWAP) (in dollars per share)	$ 0
Fair value | $	$ 0.54
Shares [Member] | Series 16 [Member]
Options, rights and restricted stock units granted as share-based payments [Abstract]
Number (in shares) | shares		687,623
Grant date		December 20, 2022
Exercise price (in dollars per share)		$ 0
Vesting Hurdle (30-day VWAP) (in dollars per share)		$ 0
Fair value | $		$ 0.775

SHARE-BASED PAYMENTS, Weighted

SHARE-BASED PAYMENTS, Weighted Average Remaining Contractual Life, Fair Value and Range of Exercise Prices (Details) - AUD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022
Weighted Average Remaining Contractual Life [Abstract]
Weighted average remaining contractual life (in years)	3 years 1 month 28 days	2 years 3 months 7 days	3 years 2 months 1 day
Weighted average fair value [Abstract]
Weighted average fair value	$ 0.53	$ 0.51	$ 0.85
Bottom of range [member]
Range of Exercise Prices [Abstract]
Exercise price (in dollars per share)	$ 0.2	$ 0.2	$ 0.2
Top of range [member]
Range of Exercise Prices [Abstract]
Exercise price (in dollars per share)	$ 0.55	$ 1.33	$ 1.33

SHARE-BASED PAYMENTS, Inputs to

SHARE-BASED PAYMENTS, Inputs to Valuation Models used for Options, Rights, and RSUs Granted (Details) - AUD ($)		11 Months Ended	12 Months Ended
		Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Jul. 19, 2020
Options [Member]
Inputs to valuation models used for instruments granted [Abstract]
Fair value at grant date (weighted average)			$ 0.491	$ 0.775	$ 0.217
Share price at grant date (weighted average) (in dollars per share)		$ 1.008	$ 0.88	$ 1.17
Vesting Hurdle (30-day VWAP) (in dollars per share)		0	0	0
Exercise price (weighted average) (in dollars per share)		$ 0.24	$ 1.03	$ 1.33
Expected life (weighted average)	[1]	5 years 29 days	3 years 3 months 21 days	3 years 11 months 26 days
Risk-free interest rate (weighted average)		1.20%	3.31%	0.175%
Expected volatility (weighted average)	[2]	100%	87%	100%
Expected dividend yield	[3]	0%	0%	0%
RSUs and Rights that Don't Have Market-based Vesting Conditions [Member]
Inputs to valuation models used for instruments granted [Abstract]
Fair value at grant date (weighted average)			$ 0.782	$ 1.115
Share price at grant date (weighted average) (in dollars per share)			$ 0.927	$ 1.115
Vesting Hurdle (30-day VWAP) (in dollars per share)			0	0
Exercise price (weighted average) (in dollars per share)			$ 0	$ 0
Expected life (weighted average)	[1]		4 years 5 months 1 day	3 years 8 months 26 days
Risk-free interest rate (weighted average)			0%	0%
Expected volatility (weighted average)	[2]		0%	0%
Expected dividend yield	[3]		0%	0%
Rights that Have Market-based Vesting Conditions [Member]
Inputs to valuation models used for instruments granted [Abstract]
Fair value at grant date (weighted average)			$ 0.322	$ 0.784	$ 0.673
Share price at grant date (weighted average) (in dollars per share)		$ 0.931	$ 0.708	$ 1.022
Vesting Hurdle (30-day VWAP) (in dollars per share)		3.01	3.49	3.65
Exercise price (weighted average) (in dollars per share)		$ 0	$ 0	$ 0
Expected life (weighted average)	[1]	4 years 6 months 25 days	3 years 6 months 3 days	4 years 3 months 10 days
Risk-free interest rate (weighted average)		1.266%	2.965%	1.317%
Expected volatility (weighted average)	[2]	100%	78%	100%
Expected dividend yield	[3]	0%	0%	0%
[1]The expected life is based on the expiry date of the options or rights.[2]The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.[3]The dividend yield reflects the assumption that the current dividend payout will remain unchanged.

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	12 Months Ended
	Jun. 30, 2023 USD ($) Segment	Jun. 30, 2022 USD ($)
Reconciliation Of Non Current Assets By Geographical Location [Abstract]
Number of operating segments | Segment	1
Non-current assets	$ 10,048,804	$ 3,819,215
United States of America [Member]
Reconciliation Of Non Current Assets By Geographical Location [Abstract]
Non-current assets	$ 10,048,804	$ 3,819,215

FINANCIAL RISK MANAGEMENT OBJ_3

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES, Credit Risk (Details) - Credit Risk [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Maximum credit risk exposure [Abstract]
Financial assets	$ 12,166,336	$ 5,945,091
Receivables past due	0
Cash and Cash Equivalents [Member]
Maximum credit risk exposure [Abstract]
Financial assets	11,937,941	5,672,551
Trade and Other Receivables [Member]
Maximum credit risk exposure [Abstract]
Financial assets	228,395	22,540
Other Financial Assets [Member]
Maximum credit risk exposure [Abstract]
Financial assets	$ 0	$ 250,000

FINANCIAL RISK MANAGEMENT OBJ_4

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES, Liquidity Risk (Details) - Liquidity Risk [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Financial Liabilities [Abstract]
Financial liabilities	$ 2,205,370	$ 2,531,718
Carrying Amount [Member]
Financial Liabilities [Abstract]
Financial liabilities	2,154,881	2,442,378
Less Than or Equal to 1 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	1,563,609	2,074,778
1-5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	641,761	452,384
Later Than or Equal to 5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	0	4,556
Trade and Other Payables [Member]
Financial Liabilities [Abstract]
Financial liabilities	1,180,984	1,899,348
Trade and Other Payables [Member] | Carrying Amount [Member]
Financial Liabilities [Abstract]
Financial liabilities	1,180,984	1,899,348
Trade and Other Payables [Member] | Less Than or Equal to 1 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	1,180,984	1,899,348
Trade and Other Payables [Member] | 1-5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	0	0
Trade and Other Payables [Member] | Later Than or Equal to 5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	0	0
Lease Liabilities [Member]
Financial Liabilities [Abstract]
Financial liabilities	990,427	588,761
Lease Liabilities [Member] | Carrying Amount [Member]
Financial Liabilities [Abstract]
Financial liabilities	943,035	506,573
Lease Liabilities [Member] | Less Than or Equal to 1 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	376,655	167,619
Lease Liabilities [Member] | 1-5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	613,773	421,142
Lease Liabilities [Member] | Later Than or Equal to 5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	0	0
Other Loans and Borrowings [Member]
Financial Liabilities [Abstract]
Financial liabilities	33,958	43,609
Other Loans and Borrowings [Member] | Carrying Amount [Member]
Financial Liabilities [Abstract]
Financial liabilities	30,862	36,457
Other Loans and Borrowings [Member] | Less Than or Equal to 1 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	5,970	7,811
Other Loans and Borrowings [Member] | 1-5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	27,988	31,242
Other Loans and Borrowings [Member] | Later Than or Equal to 5 Years [Member]
Financial Liabilities [Abstract]
Financial liabilities	$ 0	$ 4,556

FINANCIAL RISK MANAGEMENT OBJ_5

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES, Interest Rate Risk (Details) - USD ($)	11 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Jul. 19, 2020
Amount of Increase (Decrease) on Equity and Profit or Loss [Abstract]
Profit or loss	$ (13,230,837)	$ (17,444,754)	$ (21,521,237)
Equity	$ 1,760,120	$ 20,563,228	$ 7,419,719	$ 0
Floating Interest Rate [Member]
Interest-bearing financial instruments [Abstract]
Weighted average interest rate on cash at bank on hand and short-term deposits		3.09%	0.31%
Interest rate risk [member]
Interest-bearing financial instruments [Abstract]
Financial assets		$ 11,937,941	$ 5,672,551
Interest rate risk [member] | Cash at Bank and on Hand [Member]
Interest-bearing financial instruments [Abstract]
Financial assets		11,937,941	5,672,551
0.5% Increase [Member] | Cash and Cash Equivalents [Member]
Amount of Increase (Decrease) on Equity and Profit or Loss [Abstract]
Profit or loss		59,690	28,363
Equity		59,690	28,363
0.5% Decrease [Member] | Cash and Cash Equivalents [Member]
Amount of Increase (Decrease) on Equity and Profit or Loss [Abstract]
Profit or loss		(59,690)	(28,363)
Equity		$ (59,690)	$ (28,363)

FINANCIAL RISK MANAGEMENT OBJ_6

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES, Foreign Currency Risk (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
US Dollar Appreciated or Depreciated Against the Australian Dollar [Abstract]
Equity	$ (1,008,244)	$ (596,331)	$ (596,331)	$ (2,419)
Foreign Currency Risk [Member]
Financial Liabilities [Abstract]
Net exposure	8,326,535	1,601,984
Foreign Currency Risk [Member] | Cash and Cash Equivalents [Member]
Financial Assets [Abstract]
Financial assets	8,498,094	2,040,266
Foreign Currency Risk [Member] | Trade and Other Payables [Member]
Financial Liabilities [Abstract]
Financial liabilities	(171,559)	(438,282)
10% Increase [Member] | A$ [Member]
US Dollar Appreciated or Depreciated Against the Australian Dollar [Abstract]
Profit or loss	832,653	160,198
Equity	832,653	160,198
10% Decrease [Member] | A$ [Member]
US Dollar Appreciated or Depreciated Against the Australian Dollar [Abstract]
Profit or loss	(832,653)	(160,198)
Equity	$ (832,653)	$ (160,198)

FINANCIAL RISK MANAGEMENT OBJ_7

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES, Commodity Price Risk (Details) - Commodity Price Risk [Member]	12 Months Ended
	Jun. 30, 2023 USD ($)
Commodity Price Risk [Abstract]
Commodities sales forecast for next 12 months	$ 0
Hedging or derivative transaction used to manage commodity price risk	$ 0

CONTINGENT ASSETS AND LIABILI_2

CONTINGENT ASSETS AND LIABILITIES (Details)	12 Months Ended
	Jun. 30, 2023 USD ($) a Patent	Jul. 31, 2024 USD ($)	Jan. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jan. 31, 2023 USD ($)
Titan Project [Member]
Contingent Assets and Liabilities [Abstract]
Surface area of property allowed for lease or purchase (in acres) | a	10,618
Blacksand [Member]
Contingent Assets and Liabilities [Abstract]
Additional amount to be paid upon exercise of option to purchase	$ 6,000,000
Percent of purchase price to be paid in shares	30%
Amount of commitment to donate upon exercise of option to purchase	$ 1,000,000
Percent of cumulative net sales to be paid as royalty	0.50%
Blacksand [Member] | Bottom of range [member]
Contingent Assets and Liabilities [Abstract]
Number of global patents owned | Patent	40
Threshold of assets and properties for royalty payment	$ 300,000,000
Blacksand [Member] | Option Period One [Member]
Contingent Assets and Liabilities [Abstract]
Additional amount to be paid upon exercise of option to purchase					$ 1,500,000
Blacksand [Member] | Option Period Two [Member]
Contingent Assets and Liabilities [Abstract]
Additional amount to be paid upon exercise of option to purchase				$ 1,500,000
Blacksand [Member] | Option Period Three [Member]
Contingent Assets and Liabilities [Abstract]
Additional amount to be paid upon exercise of option to purchase			$ 1,500,000
Blacksand [Member] | Option Period Four [Member]
Contingent Assets and Liabilities [Abstract]
Additional amount to be paid upon exercise of option to purchase		$ 1,500,000